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Abstract 
 
Chronic diseases can affect patient’s life in a very negative way; as such, it is important and 
necessary to measure the effects of those diseases and their impact in patient's life. 
Juvenile Idiopathic arthritis (JIA) is one of chronic inflammatory diseases that affect joints all over 
the body and leads to several unwanted and maybe severe adverse events.  
In Palestine, there are no studies about JIA or its impact on pediatric patients. As such, the aim of 
this study was to indicate and measure pediatric quality of life as well as measure satisfaction with 
the treatment they receive. In addition, to determine the factors that can affect quality of life and 
treatment satisfaction. 
This study was conducted over a period of 8 months, which a total of 50 patients were included 
from two hospitals and a Specialized Pediatric Center in the West Bank under the supervision of 
their specialist pediatric rheumatologist doctor. 
Two different questionnaires were administered to the 50 patients and their parents; one of 
questionnaire is to measure the pediatric quality of life (PedsQL) Generic Core Scales form. The 
other questionnaire was to measure patient's treatment satisfaction; we used Treatment Satisfaction 
Questionnaire for Medication (TSQM) version 1.4. In addition, the study evaluated factors that 
may affect PedsQL and TSQM including patient's place of living, family relationship with patients, 
parent’s education level, type of house, family member’s number, parent’s monthly income, 
parents work status, and the cost of transportation to reveal the impact of JIA on the economic 
status. Furthermore, a correlation between PedsQL, TSQM scores with each subtype of JIA was 
determined. Finally, patient’s weight, height, and BMI effect on with TSQM or PedsQL were 
evaluated. 
Results indicate that all patients for all age groups have above average quality of life as well as 
treatment satisfaction scores. There was no significant effect except with TSQM global satisfaction 
domain, according to parent’s scores, in which the lowest score of global satisfaction was observed 
in age group of 8-12 years while the 13-18 year old age group had the highest score with significant 
difference between age groups. 
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In case of the hypothesis and comparisons, the results indicated no significant effect except of the 
following cases: 
Parents work status correlated with TSQM effectiveness domain, with the count of children’s age 
groups. In addition, Parents work status correlated with TSQM convenience domain, without the 
count of children’s age groups. The data indicates lower convenience score for working parents. 
Family member numbers correlated with PedsQL social function domain in case of no counting 
of children’s age groups. The data indicates relatively higher social function scores with increase 
in number of family members. 
In case of children’s weight and height correlation with PedsQL and TSQM, the results showed 
that both weight and height did not reveal any significant effect on PedsQL domains. On the other 
hand, there was a significant effect of height on TSQM global satisfaction domain, In which there 
was a positive relationship between them, that’s mean the increase in height indicates higher global 
satisfaction. 
In case of children’s weight, there was a significant effect with TSQM side effects domain, in 
which there is a negative relationship between them, that means that the increase in weight gives 
lower side effect scores and vice versa. 
For BMI, there was a significant effect on both PedsQL domains as well as TSQM. In case of 
PedsQL, there was a significant effect of BMI on emotional functioning and psychosocial 
functioning domains. In case of TSQM, there was a significant effect between BMI and the domain 
of convenience. In which there was a positive relationship between them; that means that the 
increase in BMI gives a higher scores with the mentioned domains. 
According to the information obtained from patient’s records, there were 4 patients with uveitis as 
a complication of JIA. For the medications used, the most commonly used medications were: 
Prednisone, Methotrexate, Ibuprofen, Folic acid. Biologics like infliximab, Etanercept, Abatacept, 
Tocilizumab, and Adalimumab were also utilized, occasionally. 
In conclusion, all 50 JIA patients have above average quality of life and treatment satisfactions 
(scores were above 50), noting that the higher the scores the better HRQoL.  
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Chapter 1: Introduction 
1.1 Background 
 
Juvenile idiopathic arthritis (JIA) is a term that covers several categories (heterogeneous group), 
each of which covers characterized signs, symptoms and different genetic framework. JIA is 
considered as the most common cause of arthritis and its related problems in children whose age 
is less than 16 years old[1-3]. JIA leads to serious disabilities in short and long term[4], the 
estimated number of JIA patients around the world up to 1 per 1000 children[5]. JIA is featured 
by pain, inflammation, swelling and limitation of motion of joints[6] accompanied with heat, or 
tenderness that commonly leads to joint destructions that affects patients quality of life[2, 6]. 
Causes of JIA are unknown[7], but there is some evidence of it including a multifactorial 
autoimmune disease with environmental and genetic contributory factors[8]. The existence of 
several subtypes of JIA and the variation of classification systems of JIA make it difficult for 
studies to clear the environmental role in JIA[9]. The most common risk factors are infections in 
addition to genetic susceptibility. Many other factors, such as maternal smoking and stress, are 
thought to contribute to the pathogenesis[10]. In case of genetic susceptibility, gene involvement 
seems complex as the disease itself may involve multiple genes regarding immunity and 
inflammation [2, 11-13]. 
 
1.2 Classification of juvenile idiopathic arthritis   
The International League of Associations for Rheumatology (ILAR) systems[14], the European 
League against Rheumatism (EULAR) and the American College of Rheumatology (ACR), are 
three classification systems suggested over the last few decades for chronic arthritis in 
childhood[1, 2]. Despite the existence of more than one classification system, none are perfect, 
this is due to several reasons including the difficulty to classify some patients into any specific 
subgroup, in addition there were patients who attain criteria for more than one subtype[2]; the 
ILAR system refers such patients to undifferentiated arthritis patients[15]. Patients who suffer 
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from juvenile spondyloarthropathies including juvenile psoriatic arthritis and juvenile ankylosing 
spondylitis were difficult to find a proper characterization and classification for them[2]. All three 
classification systems are summarized in Tables (1.1), in this thesis I will go with the ILAR system 
for classification because it was the system the doctor used with patients sample. 
Table 1: summary of chronic arthritis in children classification  
 
Summary of classification of chronic arthritis in children 
ACR (JRA) EULAR (JCA) ILAR (JIA) 
Systemic Systemic Systemic 
Polyarticular Polyarticular Polyarticular RF-negative 
Pauciarticular JRA (RF+ polyarticular) Polyarticular RF +positive 
 Pauciarticular Oligoarticular 
 Juvenile psoriatic - Persistent 
 
Juvenile ankylosing 
spondylitis 
- Extended 
 
Arthritis associated with 
inflammatory bowel disease 
Psoriatic 
  Enthesitis-related 
  Undifferentiated arthritis 
 
Because of the lack of full understanding of arthritis in children pathophysiology, the classification 
systems of JIA were built predominantly according to clinical features and findings that highly 
depend on JIA subtype[10, 16]. Classification depends on difference of disease course, number 
and locations of joints, systemic symptoms and signs, age of disease onset, and laboratory tests 
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like rheumatoid factor (RF) and ANA (anti-nuclear antibody) tests, existence of chronic or acute 
uveitis, HLA allelic associations and finally the family history of the patients[10, 16].  
ILAR classification system has been used in the last few years across a number of countries but 
recently it received a lot of criticisms[17, 18] due to the number of involved joints and the existence 
of psoriasis as parameters to describe the homogeneous disease entities has been raised as one of 
the concerns about the system[19]. Another concern is the evidence that showed antinuclear 
antibodies (ANA) in homogeneous disease subset throughout different ILAR subtypes [18, 20]. 
Therefore a need for a new discovery classification of JIA is a matter of discussion[21]. 
In the ILAR classification system there are six different subtypes of JIA according to the inclusion 
and exclusion criteria, however, there are about 20% of children with chronic arthritis that do not 
match the criteria for any category, so they are classified under additional seventh subtype called 
the undifferentiated arthritis[15, 16]. 
 
1.2.1 Oligoarticular juvenile idiopathic arthritis 
Patients who have 4 or less affected joints during the first 6 months of disease are diagnosed to 
have Oligoarticular JIA. The affected joints include mostly the lower limbs involving knees and 
ankles; the knee being more frequently affected joint as a Monoarticular onset followed by the 
ankle[22, 23] , symmetrical intervention of joints originate in less than one third of cases[24, 25]. 
In the ILAR classification system, Oligoarticular JIA itself comprises 2 more subcategories; 
persistent and extended oligoarticular JIA. In case of persistent oligoarticular JIA, the affected 
joints number remains fixed to four or fewer joints while the extended type of Oligoarticular JIA 
involves children who evolve active arthritis of five or more joints after the first 6 months of 
disease. According to statistics, about 50% of oligoarticular patients may have the extended type 
of the disease, and 30% of them will develop it in the first 2 years following diagnosis[2, 26]. Risk 
factors for extended disease encompass wrist or ankle arthritis, symmetric arthritis, hand disease, 
arthritis of two to four joints[24, 27], early disease onset (6 years), female predilection, high risk 
of iridocyclitis[28, 29], elevated erythrocyte sedimentation rate (ESR) and high frequency of 
positive ANA[24]. 
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Another concern about extended Oligoarticular JIA is that it might continue into adulthood 
according to a study that evaluated JIA patients with a period of 16.5 years of follow-up and lead 
to total remission rate of 12% in patients with extended oligoarticular JIA, compared with 75% in 
patients with persistent oligoarticular JIA[30]. 
 
1.2.2 Polyarticular juvenile idiopathic arthritis  
Patients diagnosed with Polyarticular juvenile idiopathic arthritis usually have a symmetrical 
arthritis in 5 or more joints[2, 10]. At the beginning the affected joints are the large and small one 
with metacarpophalangeal joints and wrists being the more frequent[31] throughout the initial 6 
months[2]. Patients with Polyarticular juvenile idiopathic arthritis could have an acute or insidious 
onset of manifestation[10], polyarticular split into RF-negative with 20% to 30% of JIA patients 
and RF positive with 5% to 10% of JIA patients[32]; both types affect girls usually more than 
boys[2]. 
RF-seronegative patients frequently promote polyarthritis in early childhood, in opposite to RF-
seropositive patients, who promote arthritis during latter childhood and adolescence. Another 
difference between the two types is that seronegative patients have a variable prognosis. On the 
other hand, seropositive patients are adolescent girls for the most part with severe erosive disease 
and symmetric small joint embroilment, also they may express subcutaneous nodules with non-
tender, firm lesions over pressure points and tendon sheaths characteristics.  
Polyarticular juvenile idiopathic arthritis may also affect the axial skeleton, including cervical 
spine and temporomandibular joints. Boutonniere deformities comprise the proximal 
interphalangeal joint flexion and distal interphalangeal joint hyperextension and swan-neck 
deformities with the proximal interphalangeal joint hyperextension and distal interphalangeal joint 
flexion commonly affected. Another manifestation of this subtype is the chronic uveitis 
involvement but in less frequent in comparison with oligoarticular disease[2]. 
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1.2.3 Systemic onset juvenile idiopathic arthritis (SOJIA) 
SOJIA is a unique and challenging subtype of JIA, it usually start with an extra articular phenotype 
at onset including high (39 ⁰C or higher) spiking fever that persist for 2 weeks with a typical 
intermittent pattern, exhibiting one or two daily spikes as a double quotidian, followed by fast 
return to normal baseline. Along with fever, chills appear commonly making patients look ill, but 
when the fever breaks, patient appears well [4, 33, 34]. Another extra articular manifestation that 
usually appears with fever is the discrete, circumscribed, salmon-pink evanescent erythematous 
rash that usually appears with fever spikes and disappears when the fever is gone[2, 35].  
Interesting to note that stress or a warm bath may trigger rash. 
Trunk and proximal extremities areas, including the axilla and inguinal are the most common 
places for lesions. There is a condition known as Koebner phenomenon in which it is a linear streak 
on the skin, and it could be elicited by scratching the skin. The rash is rarely pruritic and is never 
purpuric[33].  
Other extra articular manifestations including, generalized symmetrical lymphadenopathy, 
hepatosplenomegaly, and serositis; pericarditis, pleural or pericardial effusion, rarely peritonitis[2, 
4]. 
SOJIA extra-articular manifestation affects ten percent of patients only. Arthritis associated with 
SOJIA usually appear after weeks, months, or even years after the onset of systemic features and 
can exist as a single episode or become persistent[34]. Both large and small joints are affected, 
most frequently wrists and ankles[31]. 
In the diagnosis of JIA, the use of laboratory findings makes one more confident  of the diagnosis, 
finding may include anemia (which may be severe), thrombocytosis,  leukocytosis, elevated liver 
enzymes, and elevated acute-phase reactants, and ANA titer  (rarely positive)[2]. Patients with 
severe SOJIA who are inadequately treated have an increased incidence of amyloidosis (1.4%– 
9%) [2, 36]. 
SOJIA and  in a clinical view is similar to adult onset Still’s disease, it’s being the only subtype of 
JIA that not involved with age, gender, or HLA association[2, 31], SOJIA patients have a not 
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consistent course, with 60% to 85% of patients having a  remission or quiescence and up to 37% 
developing a chronic, destructive polyarthritis. 
 
1.2.4 Enthesitis-related arthritis (ERA) 
Enthesitis-related arthritis is another form of JIA that assembles psoriasis JIA with being albeit 
idiopathic in their etiology and accompany other diseases with some of their characteristics that 
can appear to resemble ERA with oligoarthritis in which ERA can affect joints of the lower 
extremity, while the sacroiliac joint is usually not affected for years[7]. ERA is more common in 
male patients children whose aged 6 years and older, and characterized by the association of 
enthesitis and arthritis together[35, 37]. 
ERA can appear with an insidious onset, with the existence of special stamped marks of pain, with 
or without objective inflammation of peripheral joints, stiffness, and eventual loss of mobility of 
the back. It is important to suspect ERA in any child with chronic arthritis of the axial and 
peripheral skeleton, or the inflammation that exist at points where tendons insert to bone 
(enthesitis). Another helpful diagnostic manifestation of ERA is the presence of enthesitis at the 
calcaneal insertions of the Achilles tendon, the plantar fascia, and the tarsal area, in conjugation of 
the seronegativity RF and ANA in most patients[2, 4]. 
Peripheral arthritis in ERA, commonly affects the joints of the lower extremities and the hip 
predominantly. In radiographic tests, changes of the joints like sacroiliac joint include joint space 
narrowing, sclerosis, erosions, osteoporosis of the pelvis, and fusion (a late finding)[38].  
ERA and inflammatory bowel syndrome could make the diagnosis a little hard due to the presence 
of arthritis in the very early stage of inflammatory bowel disease. As such, ERA may be split to 
two different types of inflammation related arthritis diseases. These are: the acute polyarticular 
form that assembles the sign and symptoms of bowel disease in a way like a mirror with arthritis 
being calmed when gastrointestinal disease become well. On the other hand, the second type is 
independent of the form of the bowel disease make it more typical of ERA. From here there is 
some manifestation can provide a clue to the right diagnosis of each of them including: the extra-
articular manifestations like anterior uveitis, aortitis, muscle weakness, aortic insufficiency,  and 
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low-grade fever, in addition to the laboratory data which can demonstrate  a normal to moderately 
elevated white blood cell count, mild anemia, thrombocytosis and elevated sedimentation rate[2, 
38].  
The bowel disease is not the only one that ERA can assemble the clinical picture, in some cases 
ERA may be suspected as ankylosing spondylitis (AS), therefore any limitation in the thorax or 
back expansion should be documented early. Patients with ERA may also manifest 
cardiopulmonary and cerebrovascular complications, which are also a remarkable cause of shorter 
life expectancy[4, 35]. 
 
1.2.5 Juvenile Psoriatic Arthritis (JPsA)  
Psoriatic arthritis is one of the other shape of JIA that although idiopathic in their etiology, but 
they also share other diseases characteristics in a high portion of patients. Psoriatic arthritis usually 
match RF polyarthritis or oligoarthritis, it is also encompass more commonly the small joints[39]. 
Particularly, psoriatic arthritis is an asymmetric arthritis that usually affects ankles, knees and the 
small joints of the hands and feet, it’s also affects the proximal interphalangeal joints, distal 
interphalangeal joints, and the tendon sheath inflammation that often lead to a diffuse  and swelling 
of the fingers called ‘‘sausage digit’’[2, 4, 40]. Psoriatic arthritis  consist of not only the articular 
parts but also involved  extra-articular manifestations like rash that develops in one third of patients 
with JPsA by 15 years of age, nail alterations that includes pitting, onycholysis, oil-drop sign, 
dactylitis as a manifestation unless rheumatoid factor is positive[2, 41]. Another extra-articular 
manifestation is uveitis, in order to prevent the asymptomatic anterior uveitis that may develop in 
up to 17% of patients. All children with JPsA should have a slit-lamp examination every 6 
months[2]. 
Patients with juvenile psoriatic arthritis (JPsA) must have arthritis and a typical psoriatic rash or 
the presence of arthritis and one of the following: family history of psoriasis in a first-degree 
relative, nail pitting or onycholysis, and finally dactylitis, in case of rash missing. There is 
increasing evidence according to the studies that JPsA is not a homogeneous disease entity, but 
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evolve at least two separated subgroups: one shares the same characteristics as early-onset ANA-
positive JIA, and the other belongs to the spectrum of spondyloarthropathies[4]. 
 
 1.2.6 Undifferentiated arthritis  
Undifferentiated arthritis is selected if patients do not meet the criteria for any of the previous six 
subtypes or patients who have characteristic under more than one subtype [27, 42]. 
 
1.3 Diagnosis: 
The diagnosis of JIA and its subtype not easy, diagnosis consists of the exclusion of all possible 
causes of chronic arthritis in childhood, and inclusion criteria. Thus, an entire clinical evaluation, 
including family to personal history with recent pathologic events, important clinical signs such as 
systemic illness, previous infection, duration of fever, rash, pain and morning stiffness, all of this 
in conjunction with appropriate radiographs and laboratory tests is needed[2, 4, 10]. A detailed 
physical examination ought to be carried out at all times of first evaluation and follow-up visits in 
order to examine all body joints[43], all of this helps to diagnose and  recognize each of JIA’s 
subtypes during the first 6 months of disease. Important clinical features are important to classify 
patients into different subtypes, that  includes the presence of inflammation at the sites of 
attachment of ligament, tendon, or fascia to bone (enthesitis), dactylitis, inflammatory lumbosacral 
pain, serositis, sacroiliitis, psoriasis, nail pitting, fever,  and rash[2]. 
The clinical symptoms of JIA can be variable. Several symptoms common in arthritis are not 
necessarily diagnostic of JIA, some symptoms and signs can overlap with other disease conditions 
specially other autoimmune diseases, this leads to a difficulty in diagnosis of JIA and may be 
mistaken with other conditions. 
Take in consideration all of the obvious information about exclusion and inclusion, the diagnosis 
of JIA and its subtypes demand a  differential diagnosis of JIA from another diseases, and maybe 
similar in manifestation diseases and abnormalities including entities in the broad categories of 
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reactive arthritis, inflammatory disease, infection, systemic disease, malignancy, and trauma (table 
1.2) [2, 10]. 
 
Table 2: Differential diagnosis of arthritis 
 
Differential diagnosis of arthritis 
Inflammatory  
Juvenile idiopathic arthritis 
 Inflammatory bowel disease 
 Sarcoidosis  
Reactive 
Postenteric 
Reiter’s syndrome 
Rheumatic fever  
Poststreptococcal 
Systemic 
Kawasaki disease 
Behcet’s disease 
Henoch-Scho¨ nlein purpura  
Serum sickness 
Systemic lupus erythematosus  
Dermatomyositis  
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Progressive systemic sclerosis  
Infection  
Septic  
Osteomyelitis 
Lyme disease 
Viral 
Bacterial sacroiliitis  
Discitis 
Malignancy 
Leukemia  
Neuroblastoma 
 Malignant bone tumors: 
Osteosarcoma 
Rhabdosarcoma 
 Ewing’s sarcoma  
Benign bone tumors: 
Osteoblastoma 
Osteoid osteoma 
Trauma  
Accidental  
Non-accidental 
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1.4 Further investigations: 
In order to make a clear diagnosis for all of JIA subtypes, additional laboratory tests can be done 
that involve complete blood examination, examination of the inflammatory markers including; 
erythrocyte sedimentation rate (ESR), and C reactive protein (CRP). Also autoimmune markers 
like rheumatoid factor (RF), HLA B27, and anti-nuclear antibodies (ANA), in addition to things 
like imaging and radiological findings[44] [45] . Radiography can reveal any narrowing of the 
joint spaces or erosions, can detect growth abnormalities in bones from an early stage or maturation 
variation. Magnetic Resonance Imaging (MRI) can uncover inflamed synovium and any raising 
joint fluid[10]. 
 
1.5 Mortality  
JIA can cause a high rate of mortality with about three to five time's higher rate than normal 
population [46-48]. This can be due to multiple factors connected to JIA complications like 
Macrophage activation syndrome (MAS) and secondary amyloidosis that increase the ratio 
especially in systemic onset JIA patients in which both complication frequently affect the 
patients[49]. However, since the involvement of cytotoxic agents into the treatment of severe JIA, 
the deaths related to amyloidosis have been reduced[47]. The increase in mortality is not only 
limited to the disease itself but also to other factors including treatment related causes, infections, 
immunosuppression, or cardiac complications, even suicides[47, 50].  
 
 1.6 Extra-articular manifestations / associated conditions 
1.6.1 Uveitis 
Uveitis is defined as inflammation of the uvea, the middle layer of the eye that is composed of 
the iris, ciliary body and choroid. Many disorders can cause uveitis including inflammatory 
diseases and that include JIA. Uveitis has more than one type that are classified by where 
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inflammation happens in the uvea; Anterior uveitis, Intermediate uveitis, Posterior uveitis, Diffuse 
uveitis [51]. 
Uveitis is one of JIA related complications that happen in about 5-20% of patients, especially with 
oligoarticular subtype, and RF polyarthritis patients, about 21% of patients with oligoarticular JIA 
develops a chronic, anterior, nongranulomatous uveitis called as iridocyclitis, and 10% of patients 
with polyarticular JIA[2]. Despite Uveitis is more common with oligoarticular and RF polyarthritis 
subtypes[49, 52], it also sometimes develops with psoriatic and enthesitis-related arthritis, on the 
other hand, none of the SOJIA patients was diagnosed with uveitis[53]. In case of ERA patients, 
acute uveitis (distinguished from the chronic form common in oligo- and polyarticular disease) 
may happen in up to 27% of patients, manifested as a unilateral recurrent, with a red, painful, 
photophobic eye, usually without sequelae[54]. 
Uveitis is usually asymptomatic, although patients may present with conjunctivitis, unequal pupils, 
eye pain, and headache[2]. Uveitis often starts at early onset stages of the course of arthritis usually 
in 4 or 5 years [25, 52, 55]. It may exist at diagnosis, develop during the course of JIA, or maybe 
exist as an initial aspect of the JIA[2]. Uveitis is most widespread in young girls with oligoarticular 
disease and a positive ANA titer [49, 52, 56], in which it may exist at diagnosis, appear during the 
course of JIA, or be an initial manifestation of the JIA. Delayed diagnosed, and poorly treated 
uveitis can cause vision loss[55, 57, 58], so patients with JIA should be screened routinely to 
prevent delay in diagnosis of uveitis[2, 53].  
 
  1.6.2 Nutrition 
Children with JIA commonly have nutritional impairment with a total caloric intake less than their 
estimated needs, in comparison with the normal daily caloric requirement for a healthy child (80 
to 120 kcal/kg/day for the first year with a decline of about 10 kcal/kg for each 3-year period)[2] . 
JIA patients usually have a smaller lean muscle mass and a high fat mass[59, 60]. In case of SOJIA 
patients, they commonly have a rise in their resting energy expenditure compared to the healthy 
one[61, 62]. All of the previous may be a result of IL-1 and TNF-a high level[63].  According to 
this, one of the important steps in treatment success is to use a dietary guidelines on for healthy 
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children according to age and sex instead of actual weight , with a dietician or nutritionist 
participation side by side with the pediatrician particularly in significant malnutrition cases[62]. 
 
1.6.3 Growth disturbance 
It is one of the most common impairment in children with rheumatic arthritis. Growth retardation 
and delayed puberty have several causes; Metabolic, Endocrinology, and Malnutrition factors[62]. 
JIA subtypes have a different average in the severity of growth disturbance; children with SOJIA 
and polyarticular disease are at greatest risk for diminished linear growth[62].  
Localized growth disturbance can result from accelerated bone maturation, micrognathia, or 
previous closure of the physis, as in brachydactyly.  Overgrowth of a lower limb may happen in a 
patient with chronic inflammation of the knee secondary to hyperemia of inflammation[23]. 
 
1.6.4 Osteopenia/osteoporosis 
As a result of the disease and its treatment effect on the body, generalized osteopenia and fractures 
increase in children with JIA, In addition to juxta-articular demineralization[64].  
Osteoporosis is known as the parallel loss of bone mineral and matrix, resulting in a bone mineral 
density (BMD) more than 2.5 SD below the mean for age and sex. Osteopenia is a low bone mass 
for age with a BMD between 1 and 2.5 SD below the mean for age and sex[65].  
Prevention of osteoporosis has become one of the important components of health care promotion 
in children with JIA, because decreased peak bone mass may increase the risk of adults having 
premature osteoporosis and increased fracture risk[2].  
 
1.6.5 Macrophage activation syndrome (MAS)  
MAS is a critical life-threatening complication of rheumatic diseases in general, especially of 
SOJIA[66, 67], manifested by excess activation of histiophagocytosis in bone marrow, also in 
lymph nodes, liver and spleen. MAS influences implicate fever, hepatosplenomegaly , 
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lymphadenopathy, and hematologic abnormalities, disseminated intravascular coagulation, and 
neurologic involvement[7, 67]. 
MAS Trigger factors maybe a viral illness, different medications alteration or addition; 
predominantly nonsteroidal anti-inflammatory drugs (NSAIDs), intramuscular gold injections, 
sulfasalazine, methotrexate (MTX), and more newly, etanercept[68].  Some biomarkers existing 
can predict MAS result in clarification of diagnosis especially in SOJIA cases; soluble interleukin-
2 receptor α, soluble CD163 (sCD163)[69-71], follistatin-like protein 1,  a glycoprotein 
overexpression[72], rise of ferritin with a drop in platelet count, serum transaminases high level, 
all of this can present as a valuable diagnostic parameters for MAS[73, 74]. 
In order to facilitate diagnosis, a multinational collaborative effort developed new classification 
criteria for the syndrome (table 1.3) [75]. 
 
Table 3: the new classification criteria of macrophage activation syndrome 
 
New classification criteria of macrophage activation syndrome  
A febrile patient with known or suspected systemic juvenile idiopathic arthritis is classified as having 
macrophage activation syndrome if the following criteria are met: 
Ferritin˃ 684 ng/ml  
and any 2 of the following: 
 Platelet count ≤ 181 × 109 /l  
Aspartate aminotransferase ˃ 48 units/l 
Triglycerides ˃ 156 mg/dl  
Fibrinogen  ≤ 360 mg/dl 
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1.6.6 Secondary amyloidosis 
Secondary or reactive generalized amyloidosis is another life threatening complication that can 
develop because of JIA; it is connected with amyloid protein obtained from the acute phase protein, 
serum amyloid A. In this case, protein deposits (amyloid) usually gather in body organs; secondary 
amyloid is a sequence of chronic infection or inflammatory disease like JIA. 
Sign and symptoms of Secondary amyloidosis comprise of hepatomegaly with cholestasis, 
digestive tract abnormalities, splenomegaly, cardiopathy, goiter, and proteinuria, which is 
considered as the first real sign of amyloidosis. 
Monitoring the acute phase response is the most important aim in secondary amyloidosis 
treatment. In the pharmacological part the use of TNF-a inhibitors may be advantageous, Cytotoxic 
agents likes chlorambucil and cyclophosphamide can be used to protect and stabilize renal 
function[7].  
 
1.7 Treatment 
The goals of treatment for JIA are suppression of clinical symptoms, therefore control pain 
inflammation process by; lowering the number of actively affected joints, preserving function, and 
promoting normal growth, overall development, well-being[2, 10]. Another goal is to prevent the 
number of disease-and/or treatment-related morbidities such as joint damage, growth disturbances, 
and functional limitations and therefore an overall quality of life[76, 77]. In order to achieve those 
aims, the medications treatment should be adjusted every three months at least and the disease 
activity should be monitored regularly every1-3 months.  
None of the available drugs have curative functions[76, 78]. Yet, during the past few years an 
increase understanding of the disease helped improve treatment, especially through earlier 
diagnosis and the development of newer medications that help to prevent long term damage to 
joints, as a result the prognosis has improved[4, 10].  
A noticeable advances in JIA treatment  have been the arrival of new disease-modifying anti-
rheumatic agents (DMARDS), and the remarkable introduction of the biologic medications, which 
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constitute a great hope for monitoring active disease in patients refractory to or intolerant of 
conventional DMARDs[2, 4, 7].  
It is important to point out the significant participation of multidisciplinary team comprising a 
pediatric rheumatologist, orthopedic surgeon, specialist nurse, physical therapist, occupational 
therapist, ophthalmologist, and psychologist, in order to reach an optimal management of a child 
with JIA[4, 35].  
 
1.7.1 Non-Pharmacological Interventions 
 
Physical therapy and occupational therapy 
 
The point of physiotherapy and occupational therapy in JIA is to improve and preserve patient's 
activity skills of their daily living with improving their muscle strength as well as range of motion 
to get back joint function and alignment. As an example, splints can be used to prevent fractures, 
and improve motion; another therapy is arthroplasty which can be use in cases of severe 
deformities[2, 4]. Other Standard physical therapy modalities are heat-cold treatment, massage, 
electrical stimulation, and ultrasound[10].  
Joint replacement, irreversible joint contractures, or dislocations can be restore by surgical 
approaches, in spite of the fact that orthopedic surgery in case of JIA is more limited than in the 
past. Prophylactic synovectomy, do not alter the long-term outcome in children with joint 
abnormalities. However, arthroscopic synoviectomy can expand remission duration in case of 
frequently relapsing joint[79]. 
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1.7.2 Pharmacological Interventions 
Nonsteroidal anti-inflammatory medications 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the conventional initial treatment for all JIA 
categories in almost all patients. However, the application for NSAIDS for more than 2 months is 
not recommended; if there still an active arthritis[4, 45], there is more common suggestion to start 
an aggressive treatment earlier in the disease course[7]. NSAIDs are not disease modifying, they 
are simply a symptomatic medications; they control pain, inflammation and usually they are given 
4 to 8 weeks duration before the initiation with a second-line agents[2, 4]. 
A few NSAIDs are approved for use in children, the most common are naproxen, ibuprofen, and 
indomethacin, with note that none has demonstrated to be superior to another[4, 80]. Those three 
NSAIDs are commonly better tolerated by children due to their little gastrointestinal discomfort in 
comparison with adults[2, 4]. The preference of use for any one of NSAIDs depends on the taste 
of the drug with the dose regimen being comparable[2]. 
Naproxen is the most frequent one in use but it must take in consideration that it can cause 
pseudoporphyria cutanea tarda, a scarring photosensitive rash in some pale skin children[81]. 
Indomethacin is one of the potent anti-inflammatory medications, usually used with ERA and 
SOJIA patients. It is important to inform patients about the possibility of headaches, difficulty in 
concentrating, and gastrointestinal upset that are commonly with indomethacin[82]. 
In children it is not that common to see serious gastrointestinal complications, however to get over 
the gastrointestinal problems related to NSAIDs, the cyclooxygenase (COX-2) inhibitors (i.e., 
celecoxib) may be useful in children experience any gastrointestinal discomfort [83-85]. 
Meloxicam, an antagonist of both COX-1 and COX-2, has confirmed to be effective and safe in 
controlled trials[86]. However, recent randomized trials clarified that the cyclooxygenase-2 
inhibitors like celecoxib, and meloxicam were no more effective or safer than naproxen[10]. 
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Glucocorticoids 
Glucocorticoids are strong anti-inflammatory medications that have a potent side-effect profile; 
cushingoid appearance, hyperglycemia, reduced growth and bone health, immunosuppression, 
cataracts and glaucoma, adrenal suppression, peptic ulcer, dyslipoproteinemia, hypertension, 
avascular necrosis of bone, and central nervous system disturbance[87]. The use of glucocorticoids 
with SOJIA who suffer from serious systemic manifestations is recommended, but in other JIA 
categories, use of glucocorticoid should be restricted to patients with more severe pain and 
functional limitation until the initiating therapy with disease-modifying anti-rheumatic drugs 
(DMARDs) and/or a biologic agent[2]. In patient with oligoarticular disease, corticosteroid usually 
are given in addition to NSAID or alone as an intra-articular injection. Intra-articular 
corticosteroids are increasingly being used and earlier in the disease course, particularly with 
oligoarticular arthritis[10, 88]. Intra-articular corticosteroids are used for treatment of a few joints 
in order to reduce inflammatory symptoms and result in functional improvement, so the need for 
regular systemic therapy can be avoided, as well as  reducing systemic side effects of oral 
medications[89, 90].  
In intra-articular corticosteroid, Triamcinolone hexacetonide demonstrated its effect in boosting 
improvement of arthritis, growth abnormalities and functional disturbances that may persist for 
many months[91, 92]. Side effects may include infection, atrophic skin changes at the injection 
site, periarticular calcifications, crystal-induced synovitis, septic arthritis and asymptomatic 
calcifications on radiographs. Injections can be presented safely every 3 months, with the note that 
the same joint should not be injected more than three times in one year[2, 4].  
The administration of systemic corticosteroids should be limited to extra-articular manifestations 
of systemic arthritis including high fever unresponsive to NSAIDs, severe anemia, myocarditis or 
pericarditis, and MAS[93, 94], also high-dose ‘‘pulse’’ intravenous methylprednisolone can be 
effective in controlling systemic manifestation of arthritis; once disease improvement is noted, 
steroids should be tapered as soon as possible. A short course of low-dose prednisone may be used 
in case of severe polyarthritis refractory while awaiting the full therapeutic effect of a recently 
initiated second-line or biologic agent[2, 4]. 
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1.7.3 Disease-modifying anti-rheumatic agents 
Patients with polyarticular disease or oligoarticular disease refractory to intra-articular steroids 
applied to DMARDs as second line agents. DMARDs that proved to be effective in JIA are 
sulfasalazine, methotrexate[2, 10]. 
Other DMARDs used in JIA include: cyclosporine, azathioprine, and cyclophosphamide, with 
cyclosporine being the less effective between them in controlling JIA, on the other hand it’s  
demonstrate its effect  in  reducing  fever in patients with systemic onset and to have a steroid-
sparing effect[7, 95], SOJIA patients have shown high response when treated  with intravenous 
cyclophosphamide and intravenous immunoglobulin[2]. 
 
Sulfasalazine  
The effect of sulfasalazine can reduce clinical arthritis and laboratory parameters of oligoarticular 
and polyarticular onset disease, disease activity [96-98]. However sulfasalazine side effect may 
restrict its use including headache, rash, gastrointestinal toxicity, myelosuppression, and 
hypoimmunoglobulinemia, therefore a routinely complete blood count and liver transaminases 
monitoring must be done every 3 months. The use of sulfasalazine declined with the development 
of newer biological DMARDs[2, 10]. 
 
Methotrexate 
Methotrexate, a folate inhibitor, since its efficacy (was proved  in a controlled trial in 1992 ) in 
controlling disease activity  and its acceptable toxic effects was demonstrated , methotrexate 
remains the most frequent widely used classical DMARD[99, 100], particularly with  polyarticular 
and SOJIA patients, its efficacy was also documented  in patients with polyarticular and 
oligoarticular extended disease[100]. 
MTX can be presented both orally and subcutaneously, with no superiority for any route in 
effectiveness.  However, there is a higher bioavailability of the subcutaneous route at increased 
doses, other reports showed an increased in efficacy after exchange from oral to subcutaneous 
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administration. On the other hand, the maximum effect of MTX was observed with parenteral 
administration of 15 mg/m2 per week, no additional advantage in giving higher doses up to 30 
mg/m2 per week[101]. 
Methotrexate side effects include gastrointestinal toxicity (the most common), occurring in 13% 
of the patients. Hepatotoxicity, oral mucosal ulcerations, teratogenicity, immunosuppression, 
pulmonary disease, pancytopenia, and an increased risk of lymphoproliferative malignancies[82, 
102].Tests to observe complete blood counts,  renal function , and liver enzymes should be done  
every 4–8 weeks (1 to 2 months) with MTX being held in any elevation of transaminases[103]. 
Take note that irreversible liver disease being rare in children[104].While the use of MTX in 
patients should be informed to not receive any live virus vaccines because of immunosuppressive 
effects of the medication. Patients in remission for 1 year can discontinue methotrexate step by 
step to restrict any possible long-term toxicity[82]. 
 
Leflunomide 
 Leflunomide is an immunosuppressive agent that reversibly inhibits de novo pyrimidine 
synthesis, therefore, lymphocyte proliferation and differentiation. Leflunomide may mimic MTX 
in effectiveness and safety, or it can be less effective than methotrexate but with similar adverse 
event rates. Therefore, leflunomide can be used as another possible option in case of MTX 
intolerance. However, the use of this medication in childhood arthritis is restricted, on the other 
hand controlled trial, leflunomide was found to be less effective than methotrexate but with similar 
adverse event rates[82, 105]. 
Leflunomide adverse event may include diarrhea, elevated liver enzymes, mucocutaneous 
abnormalities, and teratogenicity[2, 82].  
 
1.7.4 Other DMARDs  
Cyclosporine A effect was reported in severe systemic disease. Case series documented that 
Cyclosporine A might be used in macrophage activation syndrome.  However its use in juvenile 
idiopathic arthritis is limited. 
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Other synthetic DMARDs (auranofin, penicillamine, and hydroxychloroquine) do not present any 
response or effect in JIA, on the contrary of adult patients with rheumatoid arthritis findings[10]. 
 
1.7.5 Biologic agents  
In recent years, treatment options have also increased in children with juvenile idiopathic arthritis 
owing to biological medications. All biological medications used in children have been produced 
to target the etiopathogenesis leading to disease including anti-tumor necrosis factor etanercept, 
infliximab, adalimumab, the anti-interleukin 1 anakinra, anti-interleukin 6 drugs, and the B-cell 
depleter rituximab, and others[2, 76].  
 
Etanercept 
Etanercept, anti-tumor necrosis factor α (anti-TNFα)[106], is the first and for a prolonged duration 
the only registered biological medication for use in JIA[10]. The application of etanercept alone 
or in combination with MTX can be a dynamic treatment of refractory JIA for long periods (up to 
2 years) [93, 106, 107]. Etanercept improves quality of life when used for JIA[108], it also can 
affect growth velocity, bone status and reduce the progression of radiographic joint damage[109-
111].  Complete disease stillness can be achieved in half of the patients [112, 113]. Etanercept, 
when administered twice weekly as a subcutaneous injection, can give a dramatic response, 
therefore it is highly recommended for patients with extended oligoarticular and polyarticular JIA 
who have not responded to NSAIDs and methotrexate or were intolerant[2]. However, etanercept 
is less effective in patients with systemic onset JIA [94, 106, 114]. This goes back to that cytokines 
(other than TNF-a), can play a more important role in SOJIA, with IL-1,-6, and-18 representing 
the most likely candidates[7]. 
Etanercept therapy can be related to serious adverse events including injection-site reactions, upper 
respiratory tract infection, gastrointestinal symptoms headache, rhinitis, and rash[2, 115]. In 
addition to the previous side effects, some cases of varicella zoster infection were reported, and 
other cases of aseptic meningitis[116], therefore pediatric patients with exposure to varicella 
should discontinue etanercept[82]. 
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Infliximab 
Infliximab is a chimeric monoclonal anti-TNF-α antibody[117]. Response to infliximab was the 
same as etanercept, after it was unsuccessful to show any significant difference after 3 months 
according to a study, with a high frequency of serious adverse events and autoantibodies for 
patients [76, 118].   
 
Adalimumab 
Adalimumab, a humanized anti-TNF agent, was shown to have high efficacy in children and 
adolescents with JIA previously treated with other biologic agents, and patients who were either 
MTX resistant, or intolerant. Adalimumab reportedly introduce response in polyarticular patients 
[119, 120]. 
Adalimumab is admitted for use in JIA both in the USA and in Europe, as a subcutaneous injection 
every 2 weeks[4]. 
  
Abatacept 
Abatacept is a fully human soluble protein that encompasses the extracellular part of human 
CTLA4 and a fragment of the Fc region of a human IgG1. When abatacept binds to CD80/86 
molecules, it inhibit the interaction between them and CD28 receptor. 
 The binding between abatacept and the CD80/86 molecules prevents their interaction with the 
CD28 receptor and, therefore, prohibits the second signal of T cell activation [121].  
The effect of abatacept in JIA patients was observed through a double-blind randomized controlled 
withdrawal trial on a number of polyarticular JIA patients with inappropriate effect response or 
intolerance with at least one DMARD[121].  On the other hand, abatacept had better efficacy in 
patients that are unresponsive to anti-tumor necrosis factor, thereby abatacept can be used as a 
valuable alternative treatmentand is listed for JIA patients that are older than 6 years[121].  
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Anakinra  
 Anakinra considered as one of the biologics treating systemic-onset JIA patients, especially that 
systemic-onset subcategories considered one of the challenging in its treatment[122, 123]. Ankinra 
is a recombinant IL-1 receptor antagonist that showed a successful response with patient’s 
diagnosed as systemic onset JIA patients[124]. 
According to the documented observation of a controlled clinical withdrawal trial and case series, 
anakinra showed superior effects in reducing systemic symptoms in comparison to 
etanercept[125]. Today, most experts favor anakinra with systemic onset manifestations, but the 
timing of this treatment is disputable[124]. 
 
Canakinumab & rilonacept 
Canakinumab, a novel monoclonal IL-1 antibody exhibited a good efficacy and safety in children 
with systemic JIA and active systemic features[126]. Canakinumab has been approved for the 
treatment of active systemic JIA in children aged 2 years and older both in Europe and the 
USA[127].  
Rilonacept, another IL-1 antagonist [126, 128], showed a response and good tolerance in 71 
children with active arthritis in at least two joints according to a study. In comparison with anakinra 
that has a short half-life and requires a daily injection, canakinumab and rilonacept have a longer 
half-life, which enables the administration at longer intervals (every 4 weeks and weekly, 
respectively)[4]. 
 
Humanized anti-interleukin-6 receptor antibody 
According to some evidence; SOJIA is an IL-6– mediated disease, patients who received 
humanized anti-interleukin-6 receptor observed to have a significant improvement in the disease 
activity indices, in addition to a decline in the acute-phase reactants. In patients who are taking 
high-dose corticosteroids humanized anti-interleukin-6 receptor antibody can be a useful 
treatment[2, 129].  
24 
 
Tocilizumab 
 Tocilizaumab is an IL-6 receptor inhibitor[130] that was evaluated and approved by FDA for use 
for polyarticular JIA children aged 2 years and older. The most important side effects associated 
with Tocilizaumab was infection events (4.9/ 100 patient/years)[4, 131]. 
 
Autologous stem cell transplantation 
Autologous stem cell transplantation were used before biologics in patients suffering from 
autoimmune disease and it was used successfully in patients with JIA, especially for patients 
with SOJIA where medication free alleviation was observed. Autologous stem cell 
transplantation can be used as well for DMARDs, corticosteroids and biologics resistant 
patients[132]. Autologous stem cell transplantation is connected with high risks involvement 
including high relapse rates (>30%), and 9% transplant related mortality, therefore the benefit 
risk ratio must be well thought out[10, 132]. On another hand and according to some studies  
treatment using Autologous stem cell transplantation  attained  a full remission for half of the 
patients who received it after a 12-60 months of follow up[7].  
Supplements To prevent the side effects associated with some medications during treatment it is 
important sometimes to take supplements. 
Corticosteroids considering the most medications that expose patients to side effects including 
osteoporosis and osteopenia therefore there is a need to calcium and vitamin D supplements. Other 
supplements that may be beneficial for patients who are receiving methotrexate is folic acid in 
which some studies improves its effects in reducing side effects of methotrexate in addition to it 
may help to prevent the occurrence of liver enzyme abnormalities, oral ulcerations, and 
nausea[10]. 
 
1.8 Health-related quality life (HRQoL) and QoL  
Health-related quality life (HRQoL), an important measure that point out to the way an individual 
feels about particular aspects of their life with an account to their health or health condition. 
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HRQoL involves several aspects that emerged as essential health outcome in clinical improvement, 
population health assessment, clinical trials, and documenting QoL health dimensions. Its 
measurement has increased throughout the past decade towards improving patient's health as well 
as defining the importance of health care services [133-135].  
HRQoL is like an umbrella that  includes several dimensions  like patient's perceptions of the 
impact of disease and treatment functioning in a variety of at a minimum physical, psychological 
(including emotional and cognitive), and social health dimensions[133, 134] described in 1948 by 
the World Health Organization WHO.[136] 
 
1.8.1 The PedsQL (Pediatric Quality of Life Inventory) 
QoL a term cover several aspects of life aspects including health care services. Thus, HRQoL 
constitute the most suitable term for QoL health dimensions[137]. For individuals suffering from 
chronic disease, QoL measurement gives a useful route to define the impact of health care[138]. 
Since JIA can significantly affect children QoL, emotional, mental and social functions, health-
related quality of life can provide a goal for management and treatment[135]. 
The PedsQL (Pediatric Quality of Life Inventory) is designed to emphasize the child’s perceptions 
of health related quality of life (HRQoL) in children and adolescents ages 2 to 18. It is like a depot 
of several modules that are either generic or disease-specific approaches.  PedsQL are specifically 
designed for pediatric chronic health conditions that encompass forms for  Asthma, 
Arthritis/Rheumatology, Cancer, Cardiac, Brain Tumor, End-Stage Renal Disease, Diabetes 
Modules, and Cerebral Palsy, as well as the generic PedsQL Multidimensional Scale, Family 
Impact Module, Pediatric Pain Questionnaire, and the Healthcare Satisfaction Module[133, 138].  
PedsQL 4.0 Generic Core Scales is one of the PedsQL modules developed during the past 15 years. 
It measures functional status and pain. PedsQL 4.0 Generic Core Scales consist of parallel child 
self-report and parent proxy-report formats, it covers 4 dimensions (Physical function, emotional 
function, social function, and school function) that  are relevant for Juvenile Idiopathic arthritis 
patients[139]. 
26 
 
1.9 Treatment satisfaction questionnaire for medication (TSQM) 
Patient’s satisfaction with medication being an important outcome in the health outcome 
procedure. Treatment Satisfaction Questionnaire for Medication (TSQM) is a widely used generic 
measure to assess patient's satisfaction; it is a validated and reliable measurement model that helps 
understand patient’s acceptance and satisfaction with a wide variety of medications[140]. 
Enhancement of patient-focused drug was highlighted as an important aims for US Food and Drug 
Administration (FDA), by examining the Clinical outcome assessments (COAs)[141]. The TSQM 
was prepared as a self-report instrument to evaluate patients with chronic disorders. There are three 
validated versions of the TSQM: Version 1.4 (was designed as a general measure of treatment 
satisfaction with medication), Version II, and Version 9.  
TSQM Version 1.4 contains 4 domains; side effects, effectiveness, convenience (e.g. route of 
administration, dosing frequency) and global satisfaction.  All of these aspects can help in the 
treatment management and procedure. As an example, the side effects domain can point out the 
presence or lack of treatment particular adverse events to the physicians in a way that is not typical 
for clinical practice. Similarly, clinical care can be influenced by the convenience and effectiveness 
domains. In addition, some evidence indicates that patient satisfaction with their treatment 
motivates them to continue to use the medications, the adherence to medication and persistence 
with treatment dosage duration, as well as the right way of using those medications by the patients. 
These findings seem consistent for various diseases and clinical settings[140, 142].  
 
1.10 Study Objectives 
In Palestine, there are no studies about JIA, its related complication or its effect on patient's daily 
life. In addition, there are no studies about patient satisfaction with their therapy. 
From this point, the aim of this study was to investigate the effect of JIA on patient’s quality of 
life as well as their treatment satisfaction in Palestinian patients.  
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Chapter 2: Literature Preview 
 
2.1 PedsQL 
 The PedsQL Measurement construction is an assessment model to measure pediatric quality of 
life and aims to evaluate patients' and parents' awareness of HRQoL in pediatric patients with 
chronic health conditions with the use of generic, disease specific modules or both[133, 134]. 
Here we will present a number of studies that utilized Pediatric Quality of Life Inventory (PedsQL) 
as an instrument showing sensitivity, reliability, feasibility and validity. Both the general and 
Disease-Specific Modules for children with ages less than 18 are included in child self-report and 
parent proxy reports. In addition, evidence of PedsQL utility in other constructs in pediatric health 
care like quality of primary care, costs, needs and barriers are reported[133]. 
In a study in cancer patients, PedsQL was used as an instrument to measure HRQoL the study 
included 291 pediatric cancer patients and their parents. The results advocate PedsQL as a valid 
and reliable measurement for HRQoL; the study clarified the ability of PedsQL model as a measure 
in clinical and research approaches for chronic health conditions[134].  
Another study published in 2006 aimed to seek HRQoL in UK adolescents by using disease 
specific measure of JIA (JAQQ). The study assumed that as disease gets worse, the HRQoL will 
decrease. Study results indicate that the adverse events of JIA can be considerable on the HRQoL 
of JIA patients regardless of their age. The usefulness of JAQQ as a tool for HRQoL was 
established but the need for another tool for measurements that incorporate developmentally 
appropriate issues was proposed[143]. 
 
2.2 The PedsQL 4.0 Generic Core Scales 
The PedsQL 4.0 Generic Core Scales module with child self-report and parent proxy-report 
designed to measure health-related quality of life (HRQoL) in children and adolescents ages 2–
18. 
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Since 2001, PedsQL 4.0 Generic Core Scales module has been used as a measure in a number of 
published studies (greater than 345 peer-reviewed journals). The number of adolescents and 
children tested were higher than 35,000, and it has been translated into more than 65 languages. 
Those studies used PedsQL 4.0 Generic Core Scales module in both children with chronic 
conditions and in healthy children[133]. 
 
2.1.1 PedsQL 4.0 Generic Core Scales with other disease specific modules 
A study published in 2008 was designed to assess the Health-related Quality of Life in children 
receiving Chemotherapy by using 3 pediatric HRQoL measures to fulfill the study aim. They used 
2 modules of Pediatric Quality of Life Inventory (PedsQL): PedsQL 4.0 Generic Core Scales and 
PedsQL 3.0 Cancer Module, in addition to Child’s Health Questionnaire (CHQ), and the Health 
Utilities Index (HUI). They found that the PedsQL is the most responsive to change, in which there 
was significantly more change in the PedsQL generic scores when compared with the other 2 scales 
modules they used, with a 17-point change in the PedsQL generic and a 12-point change in the 
cancer module. There was less change in the CHQ and HUI scales. They concluded that the 
PedsQL should be utilized in clinical trials where there is a necessity to determine small changes 
in HRQoL[144]. 
 
2.1.2 PedsQL 4.0 Generic Core Scales and JIA  
One important thing in JIA treatment and management is the improved health-related quality of 
life (HRQoL); it became an important element that is recognized by clinicians and researchers in 
JIA disease.  Disease treatment and complications can affect all parts of children life as well as 
their family life. From this point of view, documentation of HRQoL for children diagnosed with 
JIA was done and the results showed worse HRQoL when compared to healthy controls. On the 
other hand, other studies did not report high differences in psychosocial outcomes like family 
functioning and distress, social assistance, and HRQoL[135].  
On the other hand and from the view of parent proxy-report, a number of studies proved the 
association of better parent ratings in different aspects like child well-being, pain severity, and 
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disease activity, with better child self-report. Furthermore, all of these finding supported the 
association of HRQoL with medical variables in children with JIA[135]. 
A study published in 2009 evaluated one of JIA subtypes (poly-articular JIA). The study 
highlighted the effect of this type between JIA patients, the objective of the study was utilizing the 
Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales, PedsQL Rheumatology 
Module, and PedsQL Multidimensional Fatigue Scale in order to measure HRQoL in sixty children 
diagnosed with polyarticular JIA. The results showed low PedsQL Generic Core Scales scores of 
active disease participants and also a low PedsQL Rheumatology Module scores in comparison 
with inactive JIA children. On the other hand, the r-scores were similar to the reported scores of 
the healthy controls[145]. 
 
2.3 TSQM  
Treatment satisfaction has been vastly used to evaluate the effectiveness of medical treatments 
with patients and healthcare delivery systems. Studies show that patient's satisfaction with their 
medication influences their treatment-related behaviors, including their readiness to keep on use 
the medication and their adherence with medication[146, 147].  
In a systematic review of 281 studies that evaluated the association between treatment satisfaction 
(TS) with adherence, compliance and persistence. Twenty studies showed positive associations 
between TS and treatment compliance or persistence. The studies included in this review did not 
provide a consensus on definitions of adherence, compliance, or persistence. Definitions used for 
these terms were often interchangeable across publications. In addition, there was great diversity 
in methods used for measuring satisfaction, adherence, compliance, and persistence[148]. 
TSQM was examined in several studies for chronic conditions. , For example, a study of patients 
with relapsing multiple sclerosis (RMS) that used a traditional psychometric methods as a 
comprehensive evaluation of which is the 14 item version of the TSQM (1.4 version). They found 
that TSQM gives a good assessment and met the requirements of traditional psychometric tests. 
They also found that item scores were reliable and for which evidence supported their validity as 
measures of different aspects of treatment satisfaction[142].  
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2.3.1 TSQM and JIA  
In patients diagnosed with JIA, there are a few studies and information about treatment 
satisfaction. 
In a study from Norway, an investigation of synthetic and biologic disease-modifying anti-
rheumatic drugs (sDMARDs and bDMARDs) satisfaction in adults who attended Oslo University 
Hospital from 1995– 2000, with disease duration of more than 18 months. TSQM was used with 
patients on Methotrexate (MTX) or biologics, the findings of the results showed high patient 
satisfaction in effectiveness, side effects and global satisfaction domains with biologics when 
compared to MTX. On the other hand, they found an association between age and TSQM side 
effect domain in patients treated with MTX. There was no association of disease characteristics in 
JIA with other domains of TSQM. They concluded that an incorporation of treatment satisfaction 
in the decision making of the treatment should be taken in consideration in order to assure good 
health care[149]. 
 
 2.4 In Palestine   
 2.4.1 TSQM  
With the aim of determining patient adherence and treatment satisfaction in hypertensive patients, 
a study in Palestine was designed in order to seek patient treatment satisfaction. The TSQM 1.4 
was used, the result score showed a good response with adherence, in which significant positive 
correlation was observed in total adherence and overall TSQM score. The study supported the 
ability of treatment satisfaction to be used as a reliable measurement of adherence to medications. 
They conclude that low treatment satisfaction may contribute as a barrier to patient’s adherence to 
treatment[150]. 
Another study that utilized TSQM 1.4 as a measurement tool, in a cross-sectional study that 
assessed the relationship between health-related quality of life and treatment satisfaction in 
Palestine among 385 patients with type 2 diabetes mellitus. The results did not indicate a 
significant statistical association between Overall Satisfaction and HRQoL, with 
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sociodemographic and clinical characteristics. They conclude that in order to seek a better quality 
of life among diabetic patients, elderly patients need to receive more attention in their health and 
economic status[151]. 
 
2.4.2 PedsQL 4.0 Generic Core Scales in Palestine 
In 350 preschoolers in the Gaza Strip, Palestine, a cross-sectional study was developed to evaluate 
Health-related quality of life of Palestinian preschoolers in the Gaza Strip by utilizing PedsQL 4.0 
as a measurement. The study results observed that about 65% of the children mothers indicate a 
severely impaired psychosocial and emotional functioning. The HRQoL was poor in comparison 
with US children with several chronic diseases. They conclude that Gaza Strip preschoolers have 
a severely impaired HRQoL with the association effects of both violent and non-violent negative 
events[152]. 
In another study in Gaza Strip, the Quality of Life among Children with Cancer (122 children ages 
between 7 to 18 years) was assessed using PedsQL 4.0 generic core scale. The finding observed a 
medium level of quality of life in the majority of participants, with social function domain giving 
the highest score and the emotional function domain being the lowest score[153].  
 
2.4.2 PedsQL and TSQM with JIA in Palestine 
Previously, we highlighted the importance of understanding pediatrics quality of life as well as 
patient’s treatment satisfaction as an outcome in management of disease. In Palestine, to the best 
of our knowledge, no studies determined pediatric quality of life or treatment satisfaction among 
patients with juvenile idiopathic arthritis. As such, this study is an attempt to characterize patients 
with JIA and determine the relationship between pediatric quality of life, treatment satisfaction 
and sociodemographic factors in Palestine.  
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2.5 Economic Impact of Juvenile Idiopathic Arthritis 
Juvenile idiopathic arthritis (JIA) is one of the chronic disease conditions that are able to be 
destructive to pediatrics. JIA may affect the economic part of the patients and their family, 
especially its treatment and the need to laboratory tests reporting, and physician visits every now 
and then; despite all of this, there is a low knowledge of the disease economic impact. 
Understanding the factors and information relevant to the magnitude of the health care that may 
associate and influence disease control in a better way. Treatment, health services containing 
physician’s visits and checkups, laboratory tests, and many other things should be considered in 
JIA cost[154, 155]. 
In the past 2 decades, only 1 study was published evaluating the economic cost for children with 
JIA[155, 156]. In 2009 another effort to estimate the direct medical costs in children with JIA 
compared with controls, and to determine the total direct medical costs with JIA. The findings 
showed that $1,686 total difference in annualized average direct medical costs in children with JIA 
compared to controls. They found that medication use, visits to specialists and allied health care 
professionals, in addition to diagnostic tests associated with higher cost in JIA participants. 
Furthermore, they showed the relation of higher active joint count was independently associated 
with higher total direct medical costs; the greater costs were also associated with JIA type, in which 
patients with polyarthritis or systemic JIA were relative to higher costs[155].  
 
2.5.1 Growth and weight gain impact of juvenile idiopathic arthritis 
Growth and weight abnormalities are consequences of JIA in children, the use of some treatment 
such as corticosteroids in order to manage disease leads to excessive weight gain and growth delay. 
In 2011, a report of significant height growth delay in oligoarthritis patients treated with systemic 
corticosteroids[157]. Furthermore, JIA subtypes may play a role in Growth and weight 
disturbances[158]. 
Several cross-sectional studies reported impairments in growth with JIA patients (deviation from 
healthy growth standards in height, weight or body mass index, BMI)[159]. Other studies report 
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the influence of synthetic disease modifying anti rheumatic drugs (DMARDS) and biologic 
medications on growth impairment alleviation [158, 160, 161].  
In 2017, a published study investigated the impact of JIA on height, weight and body mass index 
(BMI) development in newly diagnosed children with JIA.  They found that the majority of JIA 
children according to the subtype grew well, with the exception children who had systemic 
arthritis, uncontrolled disease activity, and/or required prolonged use of systemic corticosteroids, 
those children had a growth impairment risk[158].  
 
2.6 Pharmacists roles 
 
Pharmacists can support patients with JIA, not only by advising on their medicines but by 
counseling an issue, such as precautions during treatment (e.g. vaccinations and infections), 
complementary medicines and in particular, ensuring adherence. 
There is a highlight on the need for pharmacists and pharmacy technicians in all sectors, as part of 
the multidisciplinary team, to support children, young people and families living with JIA in a 
number of ways, including; referring when JIA is suspected, providing treatment information to 
support shared decision making, and supporting adherence to therapy, including compliance aids, 
such as monitored dosage system.  
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Chapter 3: Materials and Methods 
 
 3.1 Participants and Procedure  
 
To achieve the goal of the study, during 8 months period, patients who are formally diagnosed 
with JIA were interviewed and administered two different forms of questionnaire. The interviewed 
were done in the special rheumatologist doctor clinic located in two hospitals (AL-Makassed 
Islamic charitable society hospital Jerusalem, Caritas baby hospital in Bethlehem (CBH)) and a 
Specialized Pediatric Center.  
Due to the limited number of JIA patients in Palestine, we used convenience sample with a sample 
size of 50 patients.  
The 50 patients who participate in the study were from different places in Palestine that included 
Jerusalem, West bank, and Gaza strip. Throughout the interview, an explanation of the goal of the 
study was clarified to the participants and their family.  
Two modes of administration were used: in person and by telephone, in both modes a child self-
report and another report for parents were administered; both of the reports were in Arabic 
language. 
Both forms (the child and the proxy forms) encompass 3 different parts: the Pediatric Quality of 
Life (PedsQL) Generic Core Scales version 4.0 and the Treatment satisfaction questionnaire for 
medication (TSQM) Version 1.4 [162]. In addition, the third part covered a sociodemographic and 
socioeconomic status of both patients and their family. 
 Previously in the literature preview, there was a mention of two different questionnaire that are 
associated with Juvenile idiopathic arthritis and rheumatoid arthritis, which they are JAQQ 
(juvenile idiopathic arthritis quality of life questionnaire) and PedsQL Rheumatology Module; 
both questionnaire weren’t used in this study because they were not available as an translated 
Arabic version. 
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3.2 Measures  
 
3.2.1 PedsQL Generic Core Scales part 
 
The PedsQL measure used in this study is Pediatric Quality of Life (PedsQL) Generic Core Scales 
version 4.0 [163-169], the questionnaire was used after getting the valid Arabic version language 
questionnaire from ePROVIDETM (an online support for clinical outcome assessment). 
The questionnaire measure covers the following 4 different domains: Physical Function with 8 
items, Emotional Function with 5 items, Social Function with 5 items, and School Function with 
5 items.  
The PedsQL Generic Core Scales was administered to children with the following age distribution: 
• Teen report (ages 13-18) 
• Children report (ages 8-12) 
• Young children report (ages 5-7) 
All previous children completed a report  
About the parents/ proxy report, the participants’ parents or family completed the form of PedsQL 
with respect to children ages, the report with distributed ages were as the following: 
• Parent/proxy report for teens that ages 13-18 
• Parent/proxy report for children that ages 8-12 
• Parent/proxy report for young children that ages 5-7 
• Parent/proxy report for toddlers that ages 2-4 
The questionnaire contained phrases asking about  particular problem ‘during the past month’, the 
response to the question from the participants was applied through a 5 points score in all the 
reports, except the one for young children report (5-7 ages) in which the response is through a 3 
points sore, in order to simplifying the matter for them. For the analysis needs, those scores 
transformed to a 0 (poorest quality of life) and 100 (highest quality of life) scales.  
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3.2.2 Reliability and validity of the 23-item PedsQL 4.0 Generic Core Scales 
 
Reliability and validity of PedsQL 4.0 Generic Core Scales module was established in a 2001 
publication[139]. PedQL was administered to 1677 subjects (963 children and 1,629 parents) the 
distribution of the children from a health perspective was as follows: chronic patients, acute 
patients and healthy subjects. The study results demonstrated an acceptable reliability and 
consistency in the total score of the scale, furthermore the demonstration of its validity by the use 
of correlations and factor analysis. They found the ability of PedsQL in recognizing the differences 
between acute, chronic, and healthy children, with the relation to morbidity and illness burden 
indicators. In addition, PedsQLTM 4.0 Generic Core Scales proved its ability to extract a factor-
derived solution highly harmonious with the a priori conceptually derived scales, more 
significantly the confirmation of the role of parents’ experiences of pediatric primary care quality 
has been shown[170, 171]. 
These findings support that PedsQL 4.0 Generic Core Scales may be applicable in research, school 
health settings, clinical practice, clinical trials, and community populations[170]. 
As clarified earlier, plenty of studies used Generic Core Scales module as a sole tool or with other 
measurements of disease.  The next section will discuss studies that used Generic Core Scales 
module alone and with other disease measurement modules. 
In a clinical trial of metformin as a treatment for non-diabetic pediatric non-alcoholic 
steatohepatitis, quality of life (QoL) was used as a method novel for treatment trials in pediatric 
hepatology. The 23-item pediatric quality of life inventory (PedsQL) 4.0 was utilized. A significant 
improvement in QoL was observed after treatment. Potential reasons of this improvement 
encompass beneficial effects of metformin as a treatment, physical activity or the psychological 
support of collaborating in a clinical trial[172]. 
PedsQL 4.0 Generic Core Scales was utilized in a study designed to measure the effects of weight-
loss diets of different macronutrient compositions (low-carbohydrate low-fat group or high-
carbohydrate low-fat diets) on health-related quality of life (HRQoL), also to observe the 
correlation between changes in HRQoL domains and weight loss during weight-loss programs in 
obese adolescents.  
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Results of this study found an advanced improvement in physical, emotional, school, and 
psychosocial functioning, with an improvement in the PedsQL total score. On the other hand, low-
carbohydrate high-fat group showed no improvement[173]. 
 
3.2.3 TSQM part 
 
The TSQM version we used in this study Arabic version of TSQM (version 1.4)[162] was used as 
Arabic is the native language of the respondents. 
TSQM [162] is designed for adults age 18 and older. However, few studies used it to evaluate 
treatment satisfaction in children. In this study, we didn’t fill the TSQM questionnaire from 
children. On the other hand, parents or proxy of children with all ages completed the TSQM 
questionnaire version.   
As mentioned obviously TSQM version 1.4 [162] covers four domains:  
• Effectiveness domain focus on three items 
• Side effects domain focus on five items 
• Convenience domain focus on three items 
• and global satisfaction domain focus on three items 
Those 14 items focused on what patients think about using the medication. For each item, the 
respondent were asked to point out their level of satisfaction or dissatisfaction with the medication 
over the last two to three weeks or since the last time it was used.  
Before the patients were asked to complete the questionnaire, the interviewer explained and 
clarified everything. 
 
3.2.4 The role for parent proxy-report 
 
QoL measurements tend to cover report for both children and their parents or proxy, from the idea 
that parents are responsible for their children's health, their treatment and their perception in other 
aspects of their children, their influence and perspectives in HRQoL should to be highlighted. On 
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the other hand, there is a situation when the child is too ill or fatigued young, too cognitively 
impaired, or too young to complete HRQoL instrument, in such situation parent proxy-report may 
be required. Furthermore, the measure of health care and quality of care may be different from 
parent's perspective; therefore, their perception is important. Preferably, parent and child 
measurement instruments should evaluate the same designed forms with parallel items to make 
comparisons between self and proxy report more significant. The parent role is also just as 
important in TSQM questionnaires and other parts. 
Therefore, the forms that were completed by patient’s parents/proxy consisted of three parts: 
Part of TSQM version 1.4 questionnaire 
Part of Pediatric Quality of Life (PedsQL) Generic Core Scales version 4.0 
Part about sociodemographic and socioeconomic characteristics 
 
3.2.5 Sociodemographic part  
 
In addition to the two questionnaires, sociodemographic information part was also completed by 
the proxy/ parents that included the following: 
Patient Age (less than 5, from 5-7, from 8-12, and from 13-18)  
Patient gender (Male or Female) 
Place of living (town, village, or a camp) 
Parent’s educational level (secondary school or less, diploma, university, part of university) 
Parents/proxy relationship with the patient (Mother, Father, Others) 
Number of family members (less than 5-7, and more than 8 members) 
Accommodation status (own to the family or by rent) 
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Parents/proxy working status (housekeeper, part timer worker, not working because of the health 
status, searching for work, not working for other reasons) 
Parents/proxy monthly income(less than 1500, from 1500-3000, 3000-5000, more than 5000, or 
nothing) 
Amount of transportation fees (less than 100, from 100-400, more than 400, or by the proxy own 
car). 
 
3.2.6 Additional data collection  
 
In order to cover all characteristics and to make a full clarification of Pediatric Quality of Life 
(PedsQL) and treatment satisfaction with JIA patients, some information from patient’s record 
Were extracted under the specialist doctor supervision and with permission from the 2 hospitals 
and the special center. 
The information from patient’s record included the following: 
• JIA subtype (classified according to the ILAR system of classification). 
• The medication that was given before visiting the doctor clinic (used medication), and the 
medicine that patient’s maintained in (during follow ups). 
• Sign and symptoms of the disease that happened throughout disease duration (that was observed 
during follow ups)   
• BMI, height and weight (observation to any changes during follow-ups) 
• Lab results information (investigation): 
- ANA, RF tests 
• Observable complication that connected to the disease (Uveitis). 
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3.3 Data analysis  
 
For data analysis purpose and to test the hypotheses, IBM SPSS version 20 software was used; 
1) Descriptive statistics used (frequency and percentages) for demographic data 
2) Means and standard deviation to answer the questions of the study  
 
the use of kruskal walls and man-whitnwy tests, they are nonparametric (distribution free) test and 
they are used when the assumptions of the parametric tests are not met. Each one is used to 
compare groups, with the difference of that the man-whitnwy test was used in order to compare 2 
groups, while Kruskal-Wallis test was used to compare more than 2 groups. 
The following hypothesis were tested: 
- There are no differences in at the level of significant in PedsQL or TSQM with respect 
to JIA subtypes. 
- There is no significant difference at the level of significant in PedsQL or TSQM with 
respect to place of residence  
- There is no significant difference at the level of in PedsQL or TSQM with respect to 
family relationship to children 
- There is no significant difference at the level of significant in PedsQL or TSQM with 
respect to parents level of education 
- There is no significant difference at the level of significant in PedsQL or TSQM with 
respect to type of house 
- There is no significant difference at the level of significant in PedsQL or TSQM with 
respect to monthly income 
- There is no significant difference at the level of significant in PedsQL or TSQM with 
respect to work status 
- There is no significant difference at the level of significant in PedsQL or TSQM with 
respect to family members number 
- There is no significant difference at the level of significant in PedsQL or TSQM with 
respect to cost of transportation 
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- There is no relationship at the level of significant between BMI and PedsQL or TSQM 
- There is no relationship at the level of significant between height  PedsQL and TSQM 
- There is no relationship at the level of significant between weight   PedsQL and TSQM 
 
 
3.4 Ethical Approvals  
 
The approval to start work on this study was obtained in the first place from AL-Quds University 
ethical committee(66/REC/2019). We also connected with the TSQM [162] authors at IQVIA RDS 
Inc [162] and gained approval to use the instruments and the translated Arabic version. About 
Pediatric Quality of Life (PedsQL) Generic Core Scales version 4.0, the questionnaire was used 
after getting the valid Arabic version language from ePROVIDETM website. 
 After having the aimed questionnaire, and in order to start collecting the samples from the attended 
hospitals, the ethical approval was obtained from Caritas Baby Hospital (CBH) Medical Research 
Committee/Ethical Review, AL-Makassed Islamic charitable society hospital Jerusalem, as well 
as from the Specialized Pediatric Center. All patient's and their adult proxy gave verbal consent to 
participate in the study.  
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Chapter 4: Results  
 
4.1 Demographic characteristics 
 
The study included 50 children with their parents, children under age of 5 did not fill the 
questionnaire because of their age; this makes it 36 children and a 50 parents/ proxy who filled 
sheets. Patients were divided into 4 categories according to the age as following: below 5 years, 
from 5 to 7 years, from 8 to 12 years, and from 12 to 18 years of age. 
Demographic information included the Distribution of Children by Age Groups, Sex and Place of 
Residence as shown in Table 4.  
The study included 19 male, and 31 female children from all over, most of them are from town 
and the minimal number from camps. Demographic distribution according to parents/proxy filled 
sheet also included the, relationship with children, education level of parents, their monthly 
income, and the type of house they live in. It also included questions about parents work status and 
the cost of transportation (Table 4.4). 
 
Table 4: Parent’s demographic data Distribution of samples  
 
Category Group Frequency Percent % 
Children Age (years) 
less than 5 14 28% 
5 to 7 9 18% 
8 to 12 20 40% 
13 to18 7 14% 
Sum 50 100% 
Children gender 
Male 19 38% 
Female 31 62% 
PLACE 
City 22 44% 
Village 25 50% 
Camp 3 6% 
RELATION 
Mother 35 70% 
Father 9 18% 
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Others 6 12% 
EDUCATION 
less secondary 24 48% 
Secondary 11 22% 
Diploma 2 4% 
University 13 26% 
Place of Living 
Own 46 92% 
Rent 4 8% 
INCOME 
Less than 1500 13 26% 
1500-3000 15 30% 
3000-5000 14 28% 
more than 5000 5 10% 
None 3 6% 
WORK 
Searching 5 10% 
Working Full or Part time 16 32% 
Housekeeper 27 54% 
not working because of health status 0 0.00% 
not working for other reasons 2 4.00% 
Family Members 
less than 5 26 52% 
5 to 7 18 36% 
more than 8 6 12% 
Transportation cost group 
less than ₪100 16 32% 
₪100-₪400 20 40% 
more than ₪400 7 14% 
own car 7 14% 
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4.1.1 Juvenile idiopathic subtypes 
 
Table 5: Classification of JIA according to ILAR system  
 
Classification of  Juvenile Idiopathic Arthritis (JIA) 
Types frequency Percent 
Polyarticular arthritis 
- RF negative 4 
- RF positive 2 
- None 1 
7 14% 
Oligoarthritis 23 46% 
- Oligoarthritis (extended Oligoarthritis) 1 2% 
Systemic Arthritis 14 28% 
Enthesitis related arthritis 2 4% 
JIA (unknown) 3 6% 
Total 50 100% 
 
4.2 Questionnaires scores 
 
PedsQL and TSQM Questionnaires scores according to Parents/ Proxy sheet 
Kruskal-Wallas test was used to compare means for each axis by age groups. Total PedsQL mean 
scores showed that the best PedsQL was with 13-18 year age and it was the worst with 5-7 year 
age group. In addition, the results revealed no significant effect of any domain in case of PedsQL 
(P˃ 0.05) (Table 6).  
Similarly, TSQM domains revealed no significant difference (P˃ 0.05) for all domains with the 
exception of global satisfaction domain. The 13-18 years age group showed the highest mean value 
relative to other age groups; p-value is 0.016, which is less than 0.05 indicating significance (Table 
7). On the other hand, patients in the age group of 8-12 years old had the lowest score with the 
global satisfaction domain (Table 7). For other TSQM domains, P values showed that the domain 
of convenience was the most consistent between age groups.  
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Table 6: Parents/proxy PedsQL scores 
 
 
Age groups  
less than 5 years 5-7 years 8-12 years 13-18 years sig 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
 
Physical 
functioning 
64.06 30.17 53.29 18.79 57.81 28.18 69.32 25.91 0.620 
Emotional 
functioning 
52.14 27.30 73.89 18.67 60.25 25.05 75.00 24.83 0.113 
Social 
functioning 
82.86 21.64 71.11 18.16 77.25 18.03 88.57 11.80 0.219 
School 
functioning 
76.39 17.81 61.85 25.61 77.89 11.82 65.71 18.80 0.267 
Psychosocial 67.70 21.89 68.95 12.66 71.38 15.05 76.43 9.35 0.837 
Total PedsQL 65.55 22.08 64.21 13.59 66.60 17.89 74.06 13.29 0.670 
 
Table 7:  Parents/proxy TSQM scores 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean Std.  Dev. Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. sig 
Global 
Satisfaction 
61.22 24.05 68.25 14.34 53.10 18.88 79.59 15.66 0.016 
Effectiveness 67.06 23.72 61.73 15.33 57.78 21.13 70.63 17.19 0.283 
Side Effects 89.29 21.85 100.00 0.00 78.44 29.35 88.39 23.50 0.101 
Convenience 57.54 23.53 55.56 23.90 58.89 17.14 64.29 11.04 0.641 
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4.2.1 PedsQL Questionnaire values according to the children sheet 
In PedsQL questionnaire, the age group of less than five years did not fill the PedsQL 
questionnaire; instead, only parents/proxy filled the sheet of this category group of age. 
Total PedsQL mean scores showed that the best PedsQL was with 13-18 years old age group, and 
it was the worst with 5-7 years age group. In addition the results revealed no significant effect of 
any domain in case of PedsQL (P˃ 0.05) (Table 8). 
Table 8: Children PedsQL scores 
 
 
Age groups  
5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Physical 
functioning 
62.50 21.88 66.56 22.38 72.32 17.81 
0.666 
Emotional 
functioning 
81.11 17.64 69.75 21.06 77.14 20.18 
0.347 
Social functioning 65.56 26.51 81.25 19.99 89.29 14.27 
0.074 
School functioning 80.00 11.95 77.63 18.51 81.43 11.07 
0.847 
Psychosocial 
Health 
75.93 12.89 75.79 15.73 82.62 10.88 
0.536 
Total PedQL 71.26 13.83 72.58 16.54 79.04 12.62 
0.558 
 
Note: Only parents/proxy filled treatment satisfaction questionnaire (TSQM) 
4.3 Correlation Statistics 
This section will investigate any correlation between PedsQL or TSQM with sociodemographic 
factors like gender, place of living with respect to age groups. 
For the parents/proxy sheet, the correlation was between PedsQL or TSQM outcome with place 
living and family relationship with patients. In addition, correlation with parent’s education level, 
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type of house, family member’s number, parent’s monthly income, parents work status, and the 
cost of transportation.  
Another correlation was explored between PedsQL, TSQM scores with each subtype of JIA. 
Finally, correlation between weight, height, and BMI with TSQM or PedsQL was completed to 
reveal their outcome and effects. 
● Correlation between PedsQL and TSQM scores. 
The results showed a positive relationship between the two questionnaires scores, in which if one 
of them increased the second also increased and vice versa (Table 9). The most consistent 
positive correlation was between PedsQL scores and convenience in TSQM scores with data 
showing that convenience in treatment score was predictor of better QoL. Similarly, side effect 
domain of treatment satisfaction also showed a positive correlation with emotional functioning, 
social functioning and psychosocial domains of QoL.  
Table 9: Correlation between PedsQL and TSQM 
 
Correlations 
 
TSQM 
Global 
Satisfaction 
Effectiveness Side Effects Convenience 
PedsQL 
physical 
functioning 
Pearson 
Correlation 
0.099 0.091 0.092 0.278 
Sig. (2-tailed) 0.493 0.531 0.527 0.051 
N 50 50 50 50 
Emotional 
functioning 
Pearson 
Correlation 
0.179 0.040 0.319 0.337* 
Sig. (2-tailed) 0.213 0.783 0.024 0.017 
N 50 50 50 50 
Social functioning 
Pearson 
Correlation 
0.046 0.177 0.387 0.439 
Sig. (2-tailed) 0.753 0.218 0.006 0.001 
N 50 50 50 50 
School functioning 
Pearson 
Correlation 
0.027 -0.121 -0.091 0.269 
Sig. (2-tailed) 0.868 0.452 0.570 0.089 
N 41 41 41 41 
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Psychosocial 
Pearson 
Correlation 
0.122 0.090 0.334 0.488 
Sig. (2-tailed) 0.397 0.533 0.018 0.000 
N 50 50 50 50 
Totalpeds 
Pearson 
Correlation 
0.117 0.088 0.235 0.403 
Sig. (2-tailed) 0.419 0.543 0.101 0.004 
N 50 50 50 50 
 
● Correlation was evaluated between patient’s scores and their parents/proxy scores. 
PedsQL  scores between JIA patients and their parent’s showed no significant difference in all 
domains since P-values was less than 0.05, (tables 10). From total peds scores, children from all 
age groups indicate better PedsQL scores compared with parents/proxy opinion. On the other hand, 
children in the 5-7 year old age group revealed the lowest PedsQL compared to the other groups, 
and the 13-18 years old age showed the best PedsQL scores. In addition, for each of PedsQL 
domains, the physical functioning domain had the lowest score of all domains in the opinion of 
both children and parents/proxy. 
Table 10: Children and parents PedsQL scores comparison 
 
 
Age groups 
5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
physical 
functioning 
parent 53.29 18.79 57.81 28.18 69.32 25.91 0.911 
child 62.50 21.88 66.56 22.38 72.32 17.81 
Emotional 
functioning 
parent 73.89 18.67 60.25 25.05 75.00 24.83 0.849 
child 81.11 17.64 69.75 21.06 77.14 20.18 
Social 
functioning 
parent 71.11 18.16 77.25 18.03 88.57 11.80 0.444 
child 65.56 26.51 81.25 19.99 89.29 14.27 
School 
functioning 
parent 61.85 25.61 77.89 11.82 65.71 18.80 0.110 
child 80.00 11.95 77.63 18.51 81.43 11.07 
Psychosocial 
parent 68.95 12.66 71.38 15.05 76.43 9.35 
0.984 
child 75.93 12.89 75.79 15.73 82.62 10.88 
Totalpeds parent 64.21 13.59 66.60 17.89 74.06 13.29 
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child 71.26 13.83 72.58 16.54 79.04 12.62 
0.992 
 
4.3.1 Correlating PedsQL or TSQM with sociodemographic outcomes 
• The correlation between parents working status and PedsQL or TSQM was evaluated; 
options provided were as follows: Searching for Work, Working full or part time, full time 
housekeeper, or not working for other reasons. 
In case of TSQM outcomes, the results showed a significant effect with TSQM 
effectiveness domain (P was 0.050) (table 11). 
 
When age groups was not taken into count (Table 12), all domains showed no significant 
difference with work status (p ˃ 0.05) with the exception of TSQM domain of 
Convenience, p was 0.030, (which is less than 0.05) showing significance. This indicates 
lower convenience score in relation to work status. 
Table 11: Comparison of parents/ proxy TSQM in respect with work status and children 
age groups 
 
 
Age groups 
Less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Global 
Satisfaction 
Searc
hing 85.71 . 53.57 35.36 57.14 . 
85.7
1 
. 
0.393 
Work
ing 61.90 17.98 47.62 4.12 44.97 11.57 
71.4
3 
. 
house 
keepe
r 
65.71 23.28 73.81 20.62 60.00 22.64 
82.1
4 
18.90 
not 
worki
ng for 
. . 78.57 . . . 
64.2
9 
. 
50 
 
other 
reaso
ns 
Effectivenes
s 
Searc
hing 83.33 . 44.44 15.71 50.00 . 
55.5
6 
. 
0.050 
Work
ing 85.19 12.83 48.15 13.98 46.30 17.57 
66.6
7 
. 
house 
keepe
r 
63.89 22.41 64.81 16.04 68.89 19.81 
76.3
9 
19.44 
not 
worki
ng for 
other 
reaso
ns 
. . 77.78 . . . 
77.7
8 
. 
Side Effects 
Searc
hing 37.50 . 75.00 35.36 100. . 100 . 
0.984 
Work
ing 100 . 100. . 74.31 35.55 100 . 
house 
keepe
r 
96.25 11.86 100 .00 80.00 24.97 
84.3
8 
31.25 
not 
worki
ng for 
other 
reaso
ns 
. . 100 . . . 
81.2
5 
. 
Convenienc
e 
Searc
hing 11.11 . 36.11 27.50 55.56 . 
55.5
6 
. 
0.642 
Work
ing 64.81 17.86 40.74 21.03 54.32 10.31 
72.2
2 
. 
house 
keepe
r 
68.33 19.25 66.67 24.22 63.33 21.94 
58.3
3 
9.62 
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not 
worki
ng for 
other 
reaso
ns 
. . 61.11 . . . 
50.0
0 
. 
 
Table 12: Comparison of parents/ proxy TSQM in respect with work status 
 
Sum of 
Squares 
Df Mean Square F Sig. 
Global Satisfaction 
Between Groups 3155.761 3 1051.920 2.635 
0.061 Within Groups 18362.680 46 399.189 . 
Total 21518.441 49 . . 
Effectiveness 
Between Groups 2279.890 3 759.963 1.904 
0.142 Within Groups 18364.555 46 399.229 . 
Total 20644.444 49 . . 
Side Effects 
Between Groups 604.525 3 201.508 .327 
0.806 Within Groups 28351.725 46 616.342 . 
Total 28956.250 49 . . 
Convenience 
Between Groups 3227.469 3 1075.823 3.261 
0.030 Within Groups 15177.469 46 329.945 . 
Total 18404.938 49 . . 
 
• A comparison investigated the number of family members (with options offered being 
families less than 5 members, between 5-7 members, and more than 8 members); PedsQL 
domains showed no evidence of significance since P-value was more than 0.05.  
When Parents/ proxy scales of PedsQL and TSQM were evaluated with respect to number 
of family members (without age groups), the PedsQL Social functioning domain results 
showed a significant difference in which p was 0.05 (Table 13), it indicates relatively 
higher social function scores with higher family numbers. 
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Table 13:  Comparison of parents/ proxy PedsQL in respect with family member number 
 
 
Sum of 
Squares 
Df Mean Square F Sig. 
physical functioning 
Between Groups 452.746 2 226.373 0.307 
0.737 Within Groups 34654.604 47 737.332 . 
Total 35107.351 49 . . 
Emotional functioning 
Between Groups 3217.735 2 1608.868 2.631 
0.083 Within Groups 28744.765 47 611.591 . 
Total 31962.500 49 . . 
Social functioning 
Between Groups 2055.094 2 1027.547 3.189 
0.050 Within Groups 15145.406 47 322.243 . 
Total 17200.500 49 . . 
School functioning 
Between Groups 332.147 2 166.073 .481 
0.622 Within Groups 13116.634 38 345.175 . 
Total 13448.780 40 . . 
Psychosocial 
Between Groups 1393.326 2 696.663 2.888 
0.066 Within Groups 11337.428 47 241.222 . 
Total 12730.755 49 . . 
Totalpeds 
Between Groups 927.588 2 463.794 1.505 
0.232 Within Groups 14481.541 47 308.118 . 
Total 15409.129 49 . . 
 
4.4. JIA related Complication  
 
4.4.1 Growth impairments 
 
Investigated the relationship between PedsQL, TSQM and Height, Weight, and BMI. 
● The relationship between heights with PedsQL or Treatment satisfaction was checked, the result 
showed no relationship between height and PedsQL domains. For TSQM there was a relationship 
between TSQM domain of global satisfaction and height, P was 0.036 (less than 0.05), in which 
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there was a positive relationship between them, that means that the increase in height indicates 
higher global satisfaction (table 14). 
Table 14: Relationship between height and PedsQL or TSQM 
 Spearman's correlation Sig. 
PedsQL domains 
physical functioning -0.011 0.472 
Emotional functioning 0.185 0.123 
Social functioning 0.033 0.419 
School functioning 0.056 0.365 
Psychosocial 0.148 0.178 
Totalpeds 0.061 0.352 
TSQM domains 
Global Satisfaction 0.285 0.036 
Effectiveness 0.143 0.186 
Side Effects -0.153 0.171 
Convenience 0.202 0.103 
 
● The relationship between weights with PedsQL & Treatment satisfaction was checked, the result 
showed no relationship between weight and PedsQL domains. For TSQM there was a relationship 
between TSQM side effects domain and height, P was 0.014 (less than 0.05), in which there is a 
negative relationship between them, that means that an increase in weight gives lower side effect 
scores and vice versa (table 15). 
Table 15: Relationship between both PedsQL or TSQM with weight 
 
 Spearman's correlation Sig. 
PedsQL domains physical functioning -0.177 0.134 
54 
 
Emotional functioning -0.059 0.356 
Social functioning -0.057 0.362 
School functioning 0.003 0.493 
psychosocial -0.059 0.356 
Totalpeds -0.149 0.175 
TSQM domains 
Global Satisfaction 0.176 0.136 
Effectiveness 0.042 0.397 
Side Effects -0.344 0.014 
Convenience 0.026 0.435 
 
● The relationship between BMI with PedsQL & Treatment satisfaction was checked, the result 
showed that there was a relationship between BMI and PedsQL with emotional functioning (P was 
0.005) and psychosocial (P was 0.008) domains. For TSQM there was a relationship between 
TSQM convenience domain and BMI, P was 0.008 (less than 0.05). The observed relationship 
between them was positive, that means that the increase in BMI gives higher scores with the 
mentioned domains (table 16) 
Table 16: Relationship between both PedsQL and TSQM with BMI 
 
 Spearman's correlation Sig. 
PedsQL domains 
physical functioning 0.243 .063 
Emotional functioning 0.393 0.005 
Social functioning 0.136 0.198 
School functioning 0.181 0.129 
psychosocial 0.374 0.008 
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totalpeds 0.341 0.014 
TSQM domains 
Global Satisfaction 0.240 0.065 
Effectiveness 0.215 0.088 
Side Effects 0.148 0.178 
Convenience 0.376 0.008 
 
4.4.2 Uveitis 
 
Table 17: children with uveitis 
 
Uveitis type Frequency Percent  
uveitis (Bilateral anterior) 1 25% 
uveitis (anterior uveitis) 1 25% 
uveitis (left anterior ) 1 25% 
uveitis 1 25% 
Total 4 100% 
4.5 JIA related signs and symptoms during each follow up 
The most common side effects reported by patients before visit to the pediatric rheumatologist 
were Joint pain and joint swelling (Table 18). 
Table 18: Children signs and symptoms before the specialist doctor visit 
 
signs and symptoms 
 Frequency Percent 
 Fatigue 1 1% 
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Splenomegaly 
 
2 2% 
weight gain 1 1% 
Anemia 2 2% 
aseptic meningitis 1 1% 
back pain 1 1% 
Convulsions 1 1% 
Dactylitis 1 1% 
decreased oral intake 1 1% 
extremities pain 1 1% 
eye redness 1 1% 
febrile convulsions 1 1% 
Fever 15 12% 
gastrointestinal problems 1 1% 
high inflammatory marker 1 1% 
hip pain 1 1% 
Inability to walk 1 1% 
joints pain 25 20% 
joints Swelling 29 23% 
joints tenderness 1 1% 
knee Synovectomy 2 2% 
Limping 3 2% 
Morning stiffness 13 10% 
nail fungal infection 1 1% 
Oculocutaneous albinism 1 1% 
oral ulcers 2 2% 
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At first visit to pediatric rheumatologist, the main symptoms were joint tenderness, joint pain and 
joint swelling (Table 19). 
Table 19: Children signs and symptoms at first visit  
 
signs and symptoms 
 Frequency Percent 
 
Cushingoid 4 3% 
neck movement difficulties 2 2% 
abnormal gait 1 1% 
back pain 3 2% 
back tenderness 1 1% 
Dactylitis 1 1% 
eye redness 1 1% 
Fever 3 2% 
pericardial effusion 1 1% 
Poly arthritis 1 1% 
right arterial enlargement 1 1% 
skin rashes 6 5% 
walk difficulties 3 3% 
weight loss 3 2% 
 Sum 125 100% 
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gastrointestinal problems 1 1% 
hip tenderness 1 1% 
increased appetite 1 1% 
joint tenderness 23 16% 
joint contractures 4 3% 
joint effusion 15 11% 
joint limited movement extension 2 2% 
joint limited movement flexion 4 3% 
joints movement difficulties 1 1% 
joint pain 21 15% 
joint Swelling 27 20% 
Limited jaw opening 1 1% 
Limping 1 1% 
lymph nodes(LN) swelling 2 2% 
Moon face 1 1% 
Morning stiffness 10 7% 
muscle atrophy 1 1% 
PIPs Joints deformities 1 1% 
skin rashes 1 1% 
sleeping difficulties 1 1% 
Thigh atrophy 2 2% 
torticollis 1 1% 
walk difficulty 2 1% 
Total 139 100% 
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Children symptoms at first follow-up to pediatric rheumatologist remained joint pain and 
swelling (Table 20). 
Table 20: Children signs and symptoms at the first follow up 
 
 signs and symptoms 
 Frequency Percent 
 
Dactylitis 1 1% 
joints tenderness 4 4% 
neck movement difficulties 2 2% 
Abnormal Nails 1 1% 
back tenderness 1 1% 
Bilateral knee synovitis 1 1% 
Cushingoid 2 2% 
eyes redness 1 1% 
Fever 3 4% 
gastrointestinal problems 3 4% 
hip pain 1 1% 
hip tenderness 1 1% 
increased appetite 1 1% 
joints  contractures 2 2% 
joints effusion 6 7% 
joints limited full extension 2 2% 
Joint pain 12 15% 
Joint swelling 15 18% 
joints movement difficulties 2 2% 
joints tenderness 4 5% 
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knee swelling 1 1% 
knees effusions 1 1% 
Limping 3 4% 
Morning stiffness 6 7% 
neck pain 1 1% 
sleeping difficulties 1 1% 
Thigh atrophy 1 1% 
Tonsillitis 1 1% 
walking difficulty 2 2% 
Total 82 100% 
 
At the second follow-up visit the overall number of signs and symptoms decreased, yet joints 
pain and swelling continue to be the main complaint (Table 21). 
Table 21: Children signs and symptoms at the second follow up 
 
 signs and symptoms 
 Frequency Percent 
 
Back pain 3 5% 
back tenderness 1 2% 
Bilateral knee synovitis 1 2% 
Cough 1 2% 
Cushingoid 2 4% 
extremities pain 1 2% 
Fever 4 7% 
Gastrointestinal problems 1 2% 
hand pain 1 2% 
hip pain 1 2% 
joints Swelling 11 20% 
joints tenderness 4 8% 
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joint contracture 1 2% 
joints effusion 4 7% 
joint limited full extension 1 2% 
joints pain 12 21% 
knees  contractures 1 2% 
limited  neck movement 1 2% 
morning stiffness 4 7% 
Thigh atrophy 1 2% 
Urticaria skin rashes 1 2% 
Total 57 100% 
 
The same trend persisted with third visit with joints pain and joints swelling being the most 
commonly reported sign and symptom (Table 22). 
Table 22: Children signs and symptoms at the third follow up 
 
signs and symptoms 
 Frequency Percent 
 
Cushingoid 2 5% 
Erythematous pruritic rash 1 3% 
Fever 1 3% 
foot pain 1 3% 
gastrointestinal problems 1 3% 
hand pain 1 3% 
joints tenderness 2 6% 
joint contracture 1 3% 
joints effusion 4 10% 
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joint limited full extension 1 3% 
joints Swelling 6 17% 
joints pain 6 16% 
knee effusion 1 3% 
limited  neck movement 1 3% 
Limping 2 5% 
morning stiffness 3 8% 
Skin lesion 1 3% 
skin rashes 1 3% 
Tonsillitis 1 3% 
Total 37 100% 
 
The number of patients that came back for 4th or 5th visits was limited, the few that came in had 
joint pain and swelling as the main signs and symptoms (Tables 23 and 24). 
Table 23: Children signs and symptoms at the fourth follow up 
 
signs and symptoms 
 Frequency Percent 
 
back pain 1 7% 
enthesitis 1 7% 
gastrointestinal problems 1 7% 
Headache 1 7% 
joints effusion 2 14% 
joints  pain 3 20% 
joints Swelling 3 20% 
joints tenderness 1 7% 
Limping 1 7% 
lower extremity pain 1 7% 
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Total 15 100% 
 
Table 24: Children signs and symptoms at the fifth follow up 
 
 signs and symptoms 
 Frequency Percent 
 
joints Swelling 2 50% 
joints effusion 1 25% 
joints tenderness 1 25% 
Total 4 100.0 
 
4.6 Medications used by JIA patients during disease period and up to five  
 
follow-up visits 
 
Table 25 below, shows the medications used by patient before first visit to pediatric 
rheumatologist. The results show that the highest percentage of patients were on methotrexate 
and Prednisone. This was followed by Folic acid and NSAIDS like ibuprofen. The same trend 
with medication use was observed following visits with pediatric rheumatologist with a 
noticeable decrease in prednisone use with successive visits and more reliance of ibuprofen 
(Tables 26, 27, 28, 29, 30 and 31). 
 
Table 25: Used medications before the doctor visit (by other doctors) 
 
Used Medications 
 Frequency Percent 
 
Alfacalcidol 1 1% 
Corticosteroid joint injection 2 3% 
Cyclopentolate 1 1% 
Dexamethasone 1 1% 
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Etanercept 1 1% 
Folic acid 10 13% 
Hydroxychloroquine 2 2% 
Ibuprofen 8 10% 
Indomethacin 1 1% 
Infliximab 1 1% 
Leflunomide 2 2% 
Methotrexate 17 22% 
Naproxen sodium 2 3% 
Omeprazole 1 1% 
Paracetamol 1 1% 
Prednisolone 5 6% 
Prednisone 16 21% 
Prednisone eye drop 1 1% 
Sulfasalazine 2 3% 
Vitamin D 2 2% 
Total 77 100% 
 
Table 26: Maintained on medication at the first visit 
 
Maintained on medications 
 Frequency Percent 
 
acetylsalicylic acid (ASA) 1 1% 
Alfacalcidol 1 1% 
Calcium 3 3% 
Corticosteroid joint injection 4 4% 
Cyclosporine 1 1% 
Enoxaparin sodium 1 1% 
Etanercept 2 2% 
Ezomeprazole 7 6% 
Folic Acid 17 16% 
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Ibuprofen 17 16% 
Infliximab 1 1% 
Iron 2 2% 
Leflunomide 1 1% 
Methotrexate 20 19% 
Naproxen sodium 3 3% 
Piroxicam 1 1% 
Prednisolone 4 4% 
Prednisone 15 14% 
Ranitidine 1 1% 
Tocilizumab 1 1% 
Vitamin A + vitamin D3 drop 4 4% 
Vitamin D 2 2% 
Total 109 100% 
 
Table 27: Maintained on medication at the first follow up 
 
Maintained on medications 
 Frequency Percent 
 
acetylsalicylic acid (ASA) 1 1% 
Abatacept 1 1% 
Alfacalcidol 2 2% 
Calcium 1 1% 
Corticosteroid joint injection 4 3% 
Cyclopentolate 1 1% 
Dexamethasone 2 2% 
Enoxaparin sodium 1 1% 
Esomeprazole 6 5% 
Folic acid 24 20% 
Hdroxychloroquine 2 2% 
Hydrocortisone 1 1% 
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Ibuprofen 10 8% 
Indomethacin 2 2% 
Iron 3 3% 
Loteprednol etabonate drop 1 1% 
Meloxicam 2 2% 
Methotrexate 23 19% 
Omeprazole 3 3% 
Prednisolone 4 4% 
Prednisone 13 11% 
Ranitidine 3 3% 
Terbinafine 1 1% 
Vitamin A + vitamin D3 drop 8 7% 
Total 119 100% 
 
Table 28: Maintained on medication at the second follow up 
Maintained on medications 
 Frequency Percent 
 
Acetylsalicylic acid (ASA) 2 2% 
Abatacept 1 1% 
Adalimumab 2 2% 
Corticosteroid joint injection 4 4% 
Cyclopentolate 1 1% 
Dexamethasone 2 2% 
Esomeprazole 2 2% 
Folic acid 18 20% 
Ibuprofen 5 6% 
Indomethacin 2 2% 
Infliximab 1 1% 
Iron 3 3% 
Leflunomide 1 1% 
67 
 
Loteprednol etabonate drop 1 1% 
Maxitrol 1 1% 
Meloxicam 2 2% 
Methotrexate 17 19% 
Omeprazole 2 2% 
Prednisolone 4 4% 
Prednisone 5 6% 
Ranitidine 2 2% 
Tocilizumab 1 1% 
Vitamin A + vitamin D3 drop 6 7% 
Vitamin D 1 1% 
Total 86 97% 
 
Table 29: Maintained on medication at the third follow up 
 
Maintained on medications  
 Frequency Percent 
 
Tocilizumab 1 2% 
Abatacept 1 2% 
Acetylsalicylic acid (ASA) 1 2% 
Adalimumab 2 4% 
Cyclopentolate 1 2% 
Dexamethasone 2 4% 
Etanercept 1 2% 
Esomeprazole 2 4% 
Folic Acid 12 21% 
Ibuprofen 2 4% 
Indomethacin 1 2% 
Iron 2 4% 
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Leflunomide 1 2% 
Maxitrol 1 2% 
Meloxicam 2 4% 
Methotrexate 13 23% 
Omeprazole 1 2% 
Prednisolone 2 4% 
Prednisone 4 7% 
Ranitidine 1 2% 
Vitamin A + vitamin D3 drop 4 7% 
Total 57 100% 
 
Table 30: Maintained on medication at the fourth follow up 
 
Maintained on medications  
 Frequency Percent 
 
Abatacept 1 3% 
Acetylsalicylic acid (ASA) 1 3% 
Etanercept 1 3% 
Folic Acid 7 23% 
Indomethacin 1 3% 
Iron 1 3% 
Leflunomide 3 10% 
Meloxicam 1 3% 
Methotrexate 7 24% 
Naproxen sodium 1 3% 
Prednisolone 1 3% 
Prednisone 2 7% 
Vitamin A + vitamin D3 drop 3 10% 
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Total 30 100% 
 
Table 31: Maintained on medication at the fifth follow up 
 
Maintained on medications  
 Frequency Percent 
 
Adalimumab 1 7% 
Folic Acid 3 20% 
Indomethacin 1 7% 
Leflunomide 1 7% 
Methotrexate 3 20% 
Omeprazole 1 7% 
Prednisone 1 7% 
Tocilizumab 1 7% 
Vitamin A + vitamin D3 drop 1 7% 
Total 13 87% 
 
 
4.7 Descriptive statistics 
Means and standard deviation of PedsQL domains with respect to place of living, family 
relationship with patients, family member’s number, education level, type of house, parent’s 
monthly income, parents work status, and the cost of transportation, and family member number, 
from the parents/proxy sheet. 
Table 32. PedsQL means and standard deviation with respect to place of residence 
 
Descriptive 
 N Mean Std. Deviation 
physical functioning city 22 63.4943 26.87165 
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town 25 61.5952 25.22153 
Camp 3 27.0833 23.45485 
Emotional functioning 
City 22 65.6818 23.41629 
Town 25 60.6000 28.14842 
Camp 3 55.0000 21.79449 
Social functioning 
City 22 80.9091 18.49301 
Town 25 78.0000 20.20726 
Camp 3 78.3333 7.63763 
School functioning 
City 18 74.5370 14.07038 
Town 20 67.9167 21.49306 
Camp 3 85.0000 13.22876 
Psychosocial 
City 22 73.2828 15.77058 
Town 25 68.0111 17.02974 
Camp 3 72.7778 10.18350 
Totalpeds 
City 22 69.5792 18.27066 
Town 25 65.7856 17.98901 
Camp 3 56.8841 8.44288 
 
Table 33: TSQM means and standard deviation with respect to place of residence 
 
Descriptive 
 N Mean Std. Deviation 
Global Satisfaction 
City 22 64.9351 21.58774 
Town 25 58.4765 20.93851 
Camp 3 66.6667 17.97580 
Effectiveness 
City 22 62.3737 19.91545 
Town 25 63.5556 22.22685 
Camp 3 61.1111 14.69862 
Side Effects 
City 22 84.3750 26.56906 
Town 25 88.0000 23.79382 
Camp 3 93.7500 10.82532 
Convenience 
City 22 63.3838 14.51338 
Town 25 56.0000 22.90165 
Camp 3 46.2963 11.56481 
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Table 34: PedsQL means and standard deviation with respect to family relationship 
 
Descriptive 
 N Mean Std. Deviation 
physical functioning 
mother 35 61.1395 26.09506 
father 9 60.0694 33.90221 
others 6 56.2500 22.96397 
Emotional functioning 
mother 35 60.8571 26.91178 
father 9 70.5556 18.27643 
others 6 60.0000 28.10694 
Social functioning 
mother 35 79.5714 20.16007 
father 9 82.7778 15.63472 
others 6 72.5000 14.40486 
School functioning 
mother 28 73.6905 19.25226 
father 7 68.8095 19.47730 
others 6 68.3333 13.66260 
Psychosocial 
mother 35 70.3651 16.93624 
father 9 74.0432 14.59398 
others 6 66.9444 14.73532 
Totalpeds 
mother 35 67.0537 18.41195 
father 9 68.7639 18.54462 
others 6 63.3799 14.32125 
 
 
Table 35: TSQM means and standard deviation with respect to family relationship 
 
Descriptive 
 N Mean Std. Deviation 
Global Satisfaction 
mother 35 64.2857 22.85189 
father 9 51.3235 11.60882 
others 6 63.0952 17.15277 
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Effectiveness 
mother 35 64.9206 22.49713 
father 9 56.1728 17.22322 
others 6 61.1111 9.93808 
Side Effects 
mother 35 85.0000 24.31034 
father 9 97.2222 8.33333 
others 6 81.2500 37.50000 
Convenience 
mother 35 61.5873 20.49547 
father 9 52.4691 18.44894 
others 6 50.9259 8.90046 
 
Table 36: PedsQL means and standard deviation with respect to level of education 
 
Descriptive 
 N Mean Std. Deviation 
physical functioning 
less than secondary 24 57.2235 25.90970 
secondary 11 50.3653 27.17266 
diploma 2 56.2500 53.03301 
university 13 75.2404 20.86436 
Emotional functioning 
less secondary 24 64.7917 29.02320 
Secondary 11 60.9091 24.67977 
diploma 2 45.0000 28.28427 
university 13 62.3077 20.27061 
Social functioning 
less than secondary 24 80.8333 19.37427 
secondary 11 76.8182 20.28210 
diploma 2 65.0000 28.28427 
university 13 80.7692 16.05280 
School functioning 
less than secondary 20 69.0833 17.84825 
secondary 8 66.2500 22.95181 
diploma 1 50.0000  
university 12 82.7778 11.26659 
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Psychosocial 
Less than secondary 24 70.8912 16.03262 
secondary 11 69.0909 19.12116 
diploma 2 50.8333 22.39171 
university 13 74.4444 11.76327 
Totalpeds 
less than secondary 24 66.0274 18.94027 
Secondary 11 62.1461 15.46872 
Diploma 2 51.9324 34.15975 
University 13 74.9157 13.06514 
 
Table 37: TSQM means and standard deviation with respect to level of education 
 
Descriptive 
 N Mean Std. Deviation 
Global Satisfaction 
less than secondary 24 63.5915 20.12290 
secondary 11 60.3896 20.79139 
diploma 2 82.1429 15.15229 
university 13 56.5934 23.04638 
Effectiveness 
Less than secondary 24 63.6574 19.58912 
secondary 11 63.6364 20.98848 
diploma 2 72.2222 7.85674 
university 13 59.4017 24.15066 
Side Effects 
less than secondary 24 89.5833 21.30800 
secondary 11 89.2045 18.97591 
diploma 2 81.2500 26.51650 
university 13 80.2885 33.35086 
Convenience 
less than secondary 24 59.4907 15.49671 
Secondary 11 56.5657 29.69164 
Diploma 2 66.6667 7.85674 
University 13 57.6923 17.79202 
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Table 38: PedsQL means and standard deviation with respect to monthly incomes 
 
Descriptive 
 N Mean Std. Deviation 
physical functioning 
less  1500 13 47.4016 24.65741 
1500-3000 15 65.8929 27.36137 
3000-5000 14 62.7870 28.50729 
more than 5000 5 73.1250 23.55180 
none 3 56.2500 21.87500 
Emotional functioning 
less  1500 13 61.5385 26.56632 
1500-3000 15 62.0000 29.08117 
3000-5000 14 64.6429 21.07352 
more than 5000 5 57.0000 17.53568 
none 3 68.3333 46.45787 
Social functioning 
less  1500 13 71.9231 19.52973 
1500-3000 15 82.0000 19.89257 
3000-5000 14 83.9286 17.56073 
more than 5000 5 76.0000 17.10263 
None 3 81.6667 18.92969 
School functioning 
less  1500 11 71.5152 20.90261 
1500-3000 13 69.2308 19.45574 
3000-5000 11 78.3333 17.48015 
more than 5000 4 69.1667 16.41476 
None 2 65.0000 0.00000 
Psychosocial 
less  1500 13 66.9017 16.32121 
1500-3000 15 70.5000 19.57333 
3000-5000 14 74.8016 11.15559 
more than 5000 5 66.1111 12.32908 
None 3 75.2778 26.01193 
Totalpeds less  1500 13 60.3977 18.41949 
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1500-3000 15 68.6653 21.44928 
3000-5000 14 70.0823 13.40361 
more than 5000 5 69.3668 13.58695 
None 3 67.6329 22.94177 
 
Table 39: TSQM means and standard deviation with respect to monthly incomes 
 
Descriptive 
 N Mean Std. Deviation 
Global Satisfaction 
less  1500 13 65.3846 20.17065 
1500-3000 15 60.9524 24.72394 
3000-5000 14 54.9324 18.66462 
more than 5000 5 71.4286 15.15229 
None 3 66.6667 25.08489 
Effectiveness 
less  1500 13 64.1026 16.13590 
1500-3000 15 62.5926 21.86888 
3000-5000 14 61.9048 26.40696 
more than 5000 5 64.4444 17.82979 
None 3 61.1111 14.69862 
Side Effects 
less  1500 13 85.5769 22.87657 
1500-3000 15 87.5000 28.44559 
3000-5000 14 89.7321 22.14560 
more than 5000 5 80.0000 28.77716 
None 3 85.4167 25.25907 
Convenience 
less  1500 13 55.9829 16.42753 
1500-3000 15 59.2593 19.09166 
3000-5000 14 63.8889 21.65406 
more than 5000 5 45.5556 22.36068 
None 3 64.8148 16.03751 
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Table 40: PedsQL means and standard deviation with respect to work status 
 
Descriptive 
 N Mean Std. Deviation 
physical functioning 
Searching 5 61.2500 23.86076 
part timer 16 66.4063 33.16036 
house keeper 27 58.1900 23.59386 
not working for other reasons 2 39.0625 15.46796 
Emotional functioning 
Searching 5 53.0000 24.39262 
part timer 16 59.3750 26.63801 
house keeper 27 67.9630 24.93296 
not working for other reasons 2 37.5000 10.60660 
Social functioning 
Searching 5 67.0000 4.47214 
part timer 16 82.5000 16.53280 
house keeper 27 80.7407 20.41416 
not working for other reasons 2 65.0000 28.28427 
School functioning 
Search 2 90.0000 0.00000 
part timer 14 73.0952 16.10406 
house keeper 23 69.8551 20.55366 
not working for other reasons 2 72.5000 3.53553 
Psychosocial 
Searching 5 62.1667 15.82895 
part timer 16 70.9549 17.47602 
house keeper 27 72.8909 15.59695 
not working for other reasons 2 58.3333 4.71405 
Totalpeds 
Searching 5 61.8750 15.59715 
part timer 16 69.2196 20.96109 
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house keeper 27 67.6254 16.58008 
not working for other reasons 2 51.6304 2.30578 
 
Table 41: TSQM means and standard deviation with respect to work status 
 
Descriptive 
 N Mean Std. Deviation 
Global Satisfaction 
Searching 5 67.1429 24.53652 
part timer 16 50.2980 13.85202 
house keeper 27 66.9312 22.33857 
not working for other reasons 2 71.4286 10.10153 
Effectiveness 
Searching 5 55.5556 18.00206 
part timer 16 55.2083 21.41773 
house keeper 27 67.6955 19.79459 
not working for other reasons 2 77.7778 0.00000 
Side Effects 
Searching 5 77.5000 31.12475 
part timer 16 85.5469 29.11174 
house keeper 27 88.8889 21.11192 
not working for other reasons 2 90.6250 13.25825 
Convenience 
Searching 5 38.8889 22.90614 
part timer 16 54.8611 15.43272 
house keeper 27 64.8148 19.05906 
not working for other reasons 2 55.5556 7.85674 
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Table 42: PedsQL means and standard deviation with respect to family member’s numbers 
 
Descriptive 
 N Mean Std. Deviation 
physical functioning 
less than 5 26 57.4691 27.20727 
5-7 18 63.4755 26.60621 
more than8 6 63.5417 28.68652 
Emotional functioning 
less than 5 26 55.3846 27.60156 
5-7 18 72.7778 20.80881 
more than8 6 62.5000 21.62175 
Social functioning 
less than 5 26 74.0385 19.39171 
5-7 18 82.2222 16.73515 
more than8 6 93.3333 14.02379 
School functioning 
less than 5 21 73.0159 17.26926 
5-7 16 69.1667 21.10819 
more than8 4 78.7500 12.50000 
Psychosocial 
less than 5 26 65.6838 16.95204 
5-7 18 74.9383 13.64177 
more than8 6 79.0278 14.06746 
Totalpeds 
less than 5 26 62.8055 19.19873 
5-7 18 71.0009 15.15415 
more than8 6 72.5127 16.50903 
 
Table 43: TSQM means and standard deviation with respect to family member’s number 
 
Descriptive 
 N Mean Std. Deviation 
Global Satisfaction 
less than 5 26 58.7912 21.31472 
5-7 18 68.1221 19.10178 
more than8 6 55.9524 23.65426 
Effectiveness less than 5 26 60.8974 22.79705 
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5-7 18 62.0370 17.59403 
more than8 6 74.0741 17.45069 
Side Effects 
less than 5 26 82.2115 25.16771 
5-7 18 94.0972 15.82188 
more than8 6 84.3750 38.27328 
Convenience 
less than 5 26 54.9145 20.86564 
5-7 18 61.4198 16.66364 
more than8 6 66.6667 19.56313 
 
Table 44: PedsQL means and standard deviation with respect to cost of transportation 
 
Descriptive 
 N Mean Std. Deviation 
physical functioning 
less than 100 
10 67.9911 19.87379 
100-400 
23 61.9824 24.65069 
more than 400 
10 50.3125 33.76832 
my car 
7 58.4821 32.26045 
Emotional functioning 
less than 100 
10 68.5000 23.10002 
100-400 
23 66.9565 26.78785 
more than 400 
10 52.5000 17.67767 
my car 
7 53.5714 32.10845 
Social functioning 
less than 100 
10 77.5000 22.63846 
100-400 
23 79.5652 17.70420 
more than 400 
10 83.5000 17.80293 
my car 
7 75.0000 20.41241 
School functioning 
less than 100 
10 70.5000 21.53163 
100-400 
17 74.3137 19.07641 
more than 400 
8 72.5000 16.03567 
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my car 
6 67.7778 16.92029 
Psychosocial 
less than 100 
10 72.1667 15.09333 
100-400 
23 73.0556 17.04865 
more than 400 
10 68.4167 12.91263 
my car 
7 63.5317 19.25617 
Totalpeds 
less than 100 
10 70.7684 15.03914 
100-400 
23 68.8640 17.88082 
more than 400 
10 62.1837 16.19294 
my car 
7 61.8062 23.58432 
 
Table 45: TSQM means and standard deviation with respect to cost of transportation 
 
Descriptive 
 
N Mean Std. Deviation 
Global Satisfaction 
less than 100 
10 56.9054 26.73607 
100-400 
23 66.4596 20.48063 
more than 400 
10 50.7143 13.23518 
my car 
7 69.3878 17.84013 
Effectiveness 
less than 100 
10 53.8889 20.79523 
100-400 
23 65.9420 21.20820 
more than 400 
10 59.4444 16.77945 
my car 
7 70.6349 21.44816 
Side Effects 
less than 100 
10 80.0000 28.98755 
100-400 
23 86.6848 27.52222 
more than 400 
10 87.5000 17.92151 
my car 
7 95.5357 11.81139 
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Convenience 
less than 100 
10 59.4444 19.43121 
100-400 
23 60.8696 19.20694 
more than 400 
10 50.5556 23.49007 
my car 
7 61.9048 13.39053 
 
Table 46: Weight, height, and BMI during 5 follow ups means and standard deviations 
 
Descriptive  
 Mean Std. Deviation 
Weight 26.48 12.75 
Weight f1 25.88 13.23 
Weight f2 26.47 13.36 
Weight f3 29.37 13.87 
Weight f4 30.32 12.68 
Weight f5 28.47 7.81 
Height 116.86 24.19 
Height f1 117.09 25.27 
Height f2 115.90 26.19 
Height f3 121.32 24.13 
Height f4 128.42 22.59 
Height f5 126.50 17.02 
BMI 18.47 4.93 
BMI f1 18.11 4.74 
BMI f2 19.10 5.55 
BMI f3 17.87 2.07 
BMI f4 18.30 2.00 
BM If5 17.33 1.53 
F refers to follow up; f1 follow up 1, f2 follow up 2…etc 
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Chapter 5: Discussion 
 
This study characterized 50 patients formally diagnosed with JIA with the oversight of the 
specialist pediatric rheumatologist doctor. The patients attended pediatric rheumatology clinic in 
AL-Makassed Islamic charitable society hospital in Jerusalem, Caritas baby hospital (CBH) in 
Bethlehem and a Specialized Pediatric Center. 
The ILAR system was used as a classification protocol by the pediatric rheumatologist doctor; 
most patients (48%) were diagnosed with oligoarthritis; that included one patient (2%) who was 
diagnosed as an extended oligoarthritis patient, that was followed by Systemic Arthritis (28%), 
Polyarticular arthritis (14%), Enthesitis related arthritis (4%), and 3 patients (6%) were not 
classified. For polyarthritis diagnosed patients, 4 patients were rheumatoid factor negative, 2 
patients were rheumatoid factor positive, and one patient RF was unknown (RF test was not done). 
This study included 31 females and 19 males, this is consistent with literature reports that 
autoimmune disease is more common in females than males[174]. 
The main objective of this study was to determine the impact of JIA on Palestinian children’s 
quality of life and to measure patient’s treatment satisfaction.  
Our results showed that JIA patients indicate a relatively good quality of life from the opinion of 
children patients. As that the higher scores indicates better HRQoL. According to PedsQL results, 
the mean of each domain and age group was higher than 50; more than the half, with the physical 
functioning domain being the lowest (tables 8). On the other hand, parents scores was lower than 
the children scores in all domain except for the children who aged from 5-7 in the social 
functioning domain, but there was no significant effect in any of PedsQL domains (table 10). 
 This finding is inconsistent to another study results by Ringold et al[145], which found a lower 
scores in all of PedsQL domains when they compared active polyarticular juvenile idiopathic 
arthritis patients with inactive patients scores, the parents scores also gives a lower scores with a 
big difference in the domain of physical health.  
For TSQM, results showed a relatively high satisfaction, it did not reveal any negative effects from 
parents opinions, except for the domain that’s cover the global satisfaction part (p= 0.016) (Table 
7). That significant effect may be was due to the big fear of some patient's parents that the given 
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medication may not provide a good benefit for their children, or that the medications positive 
effects may be less than the negative ones especially with the bad reputation of some medications 
like corticosteroids. The same observation can be made with DMARDs and methotrexate, in which 
some parents may discontinue their children’s therapy because they are not sure that the 
methotrexate will not harm their children even if they see the good results and that their children 
health becomes better. In addition, these thoughts make parents delay their follow up visits to the 
doctor.  Data obtained from patient's records show that the numbers of follow or checkups were 
low, it is important to notice that some patients visited their doctor only once, some of them twice; 
others had 4 visits, with 5 times as maximum. The periods between those visits were long for some 
patients while for others it was short. 
 In a study that attend to investigate the synthetic and biologic disease-modifying anti-rheumatic 
drugs (sDMARDs and bDMARDs) treatment satisfaction in patients with Juvenile Idiopathic 
Arthritis, their results showed a higher treatment satisfaction with biologics compared to MTX in 
the domains side effects, effectiveness and global satisfaction. They also found a linkage between 
TSQM domain of side effects and age patients using MTX. Most importantly their results didn’t 
reveal any association between TSQM domains and JIA characteristics[149]. 
It is important to note that other reasons may also affect doctor visits, for example the long 
distances and poor transportation. Another important reason may refer to the limited income, 
which may affect several aspects from the inability to pay treatment expenses and all of diagnostic 
procedure, including the expenses of tests, especially with the need of regular retests for some or 
specific things like CBC and others. Finally, those limitation may affect their ability to reach the 
doctor, from an economic review about 40% of patient's parents have to pay about 100-400 NIS 
for transportation expenses, and 14% of them exceeded the boundaries of 400 NIS. 
As a result of the previous information, we evaluated the relationship between quality of life or 
treatment satisfaction from patient's parent opinions (as they are officially responsible for the 
children) with sociodemographic and economic aspects: Parent education level, type of house, 
proxy work status, proxy monthly income, family member’s number and finally cost of 
transportation to the doctor clinic (Results chapter and appendix D). 
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The results showed that for all of those sociodemographic and economic aspects there was no 
significant difference for all of quality of life as well as TSQM domains. From the aspect of number 
of family members, an exception was observed in the results in which PedsQL social functioning 
domain was significantly different (P was 0.05), when patients age group was not counted. 
In a study by Bernatsky, S., et al, they investigated the effect of JIA as a chronic disease on the 
costs of medications when it was compared to the control, the study results pointed that JIA 
patients related with a  higher costs with several aspects, including health care professionals visits, 
diagnostic tests and medications. They also found that JIA costs can be higher that other chronic 
disease like asthma, because of the medications high costs[155].  
Away from economic issues and its related problems, and for the assurance of covering all aspects 
that may affects pediatric quality of life and their treatment satisfactions matters, we investigated 
the effect of each subtype of JIA and both questionnaire domains. The results showed a good 
quality of life as well as a good treatment satisfaction in all subtypes of JIA (appendix D).  
It is important to observe that there were a number of symptoms during patient’s period of disease, 
as noted from information extracted from patient's records; those symptoms  most commonly 
included joint swelling and pain  followed by joint tenderness, joint effusion, and morning 
stiffness, with all of them counted as characteristic signs of JIA in children.  On the other hand, 
there was a side effect related of treatment itself that included cushengoid syndrome, weight 
abnormalities, oral ulcers, gastrointestinal problems and others (Tables 18-24). 
According to the information extracted from patient records, we found that some patients 
developed an associated complication with JIA that includes uveitis, we found four patients with 
uveitis; one of those patients diagnosed with bilateral uveitis, and two were diagnosed with anterior 
uveitis (Table 17). 
Uveitis associated with JIA can be very harmful , some study indicated that JIA can reveal the 
worst visual prognosis between all of systemic diseases[175]. 
On the other hand, early diagnosis and the good treatment of JIA may end out with less uveitis 
severity, in a study for Edelsten et al[176]. The study was made on two groups of uveitis patients, 
one of them is patients who are diagnosed with JIA and the other are not diagnosed with JIA. The 
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results showed that if JIA was not diagnosed, patients developed complication related to uveitis 
more than the group of diagnosed patients. Moreover, the study showed that in case of non-
diagnosed patients, uveitis was more severe at onset and it was associated with complication like 
glaucoma, cataract extraction and poor vision. The authors also refer to a high rate of loss of vision 
in the group of not diagnosed patients more than the group of diagnosed. 
 We were also interested in the effects of JIA on the growth, from the information we have, we 
were able to observe that height, weight of children during different periods according to their 
follow-ups and therefore we were able to calculate the BMI. Both weight and height showed a 
decrease at first, then increasing, then decreasing during the disease period. But, as children and 
teenagers growth may be going fast suddenly especially during their puberty with the possibility 
to gain or lose weight during this period, therefore the use of Height and weight alone are not truly 
proper indicators. So BMI was also calculated as a proper tool to indicate obesity, overweight or 
under normal weight in children. 
It is known that chronic inflammation with JIA patients may develop a delay in growth and poor 
weight gain[158]. The effect of corticosteroid as a treatment to control inflammation may also lead 
to weight gain and growth delay. As such, we attempted to observe the effects of each one of 
weight, height, and BMI on patient’s treatment satisfaction as well as their PedsQL. Results 
showed that all of PedsQL domains were not significantly affected when checked with children 
height and weight. On the other hand, TSQM Global Satisfaction domain P value was 0.036 
indicating a significant difference. In case of the correlation between weight and PedsQL, the 
results reveal no significance relationship. On the other hand, TSQM correlation with weight 
showed a significant effect with the domain of side effects (P was 0.014).  However, when the 
correlation was checked with BMI, the results showed a significant effect in the Emotional 
functioning domain (P was 0.005) and psychosocial domain (P was 0.008) of PedsQL and 
therefore a significant effect on the total PedsQL (P was 0.014). On the other hand, the correlation 
between TSQM and BMI gives significant effect with the Convenience domain (P was 0.008). 
During disease period, the use of corticosteroids (especially systemic corticosteroids) with the fear 
of them from children parents may in some way or another affect the score of both treatment 
satisfaction as well as PedsQL. 
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Guzman, J., et al., found that most of the JIA patients in their study were similar to other children 
in whom they gained weight and grew well, except for some children with systemic arthritis, and 
some patients who required a long use of systemic corticosteroids, in which they were at 
impairments in growth probability dangers[158].     
In addition to corticosteroids, one of the most frequent medications in use with children throughout 
follow-up was methotrexate and folic acid, as folic acid may decrease and affect methotrexate side 
effects[177]. Folic acid was not the only one that was used with patients to support their health but 
also there was a use of other vitamins and minerals that include iron, vitamin D, calcium, and 
others (tables 25-31). With NSAIDs being in the first class treatment, the most used one was 
ibuprofen as it is the only one that exists in liquid dosage form, in addition that ibuprofen is one 
of the most used NSAIDs in JIA[4]. As NSAIDs can be a cause of unwanted gastrointestinal 
problems, so the use of gastroprotective co-therapy is recommended [178],  our results showed the use 
of PPI in which they can reduce gastrointestinal side effects. As for biologics, they used infliximab, 
Etanercept, Abatacept, Tocilizumab, and Adalimumab (tables 25-31). 
As indicated in the results, the medications included the use of antibiotics before patient being 
admitted to the doctor’s clinic, or during the disease period, due to the ability of microbiological 
infections especially with the use of treatment that reduce the immune system activity. 
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Chapter 6: Conclusion 
 
Juvenile Idiopathic Arthritis (JIA) is a chronic disease of arthritis in children.  
JIA symptoms can be severe and may affect patient’s life to a great extent with severe 
complications that will surely be highlighted as significant marks in patient’s life in many different 
ways. 
Mean PedsQL and TSQM scores of 50 JIA patients were above average for quality of life and 
treatment satisfaction (scores were above 50). Questionnaire guidelines indicate that the higher the 
score the better HRQoL and treatment satisfaction. Total PedsQL and TSQM mean scores were 
>64 and >53 for all domains, respectively.   
PedsQL scores appear similar for all age groups since no statistical significant difference was 
observed as a function of age. Similarly, PedsQL scores for all domains were similar for 
parent/proxy and children responses.  
For TSQM, the lowest score for global satisfaction was measured for 8-12 years old age group and 
the highest score was for 13-18 years old age group with the difference showing statistical 
significance, meaning that global satisfaction domain of treatment improves with patient's age. 
Correlation between PedsQL and TSQM domains shows that convenience in treatment score was 
predictor of better QoL. As such, the health care system should do everything possible to make 
appointments and treatments as convenient as possible to JIA patients and their parent. Similarly, 
treatments that result in less side effect correlated with better QoL. Most of the side effects one 
can anticipate comes from the use of corticosteroids. As such, every effort should be made to use 
the lowest dose possible for the shortest duration in order to reduce side effects and improve JIA 
patients QoL. 
Parents work status showed a significant relationship with TSQM convenience domain. As such, 
particular attention should be paid to working parents/proxy to try to make doctor appointments 
and patient treatment as convenient as possible in order to increase treatment satisfaction. 
There was a significant relationship between the number of family members with PedsQL social 
function domain in parent/proxy evaluation. It is not surprising to find that higher number of family 
members results in higher social function scores. 
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Parents/proxy of JIA patients want to see their children grow and live a normal life. As such, it is 
not surprising to see improved global satisfaction (TSQM) with increase in children height. The 
relationship between children weight and side effect domain (TSQM) maybe related to the use of 
corticosteroids that are known to result in increased weight and water retention.  
Finally, the significant relationship of BMI with emotional functioning and psychosocial 
functioning domains of PedsQL seems to be related to the children growing and having an active 
fulfilling life. Similarly, the significant relationship between BMI and convenience domain 
(TSQM), suggests easier management in treatment and movement as patients grow and BMI 
increases. 
The number of patients that participated in the study may affect these results therefore; further 
follow-up investigation about the effects of JIA at pediatric life are recommended. 
Patients Treatment Satisfaction with their medication can potentially have an affect on their 
treatment-related behaviors, such as their willingness to continue to use the medication and their 
adherence to medication, hence impacting the success of treatment outcomes.  Parents work status 
making them more busy to find a time to communicate with their children doctor, and also 
influence treatment doses leading to non-adherence. 
Non-adherence is a risk factor for a variety of subsequent poor health outcomes, including quality 
of life. 
The advice given to patients by their healthcare professionals to control disease is too often 
misunderstood, carried out incorrectly, forgotten, or even completely ignored, Even when 
information is communicated effectively and comprehension is initially high, much of what is 
conveyed during the medical visit is forgotten within moments of leaving the doctor's office. When 
physicians erroneously assume that their patients have taken prescribed medication(s), they may 
make inappropriate medication and/or dosage changes, which can then result in further 
complications and suboptimal health outcomes. Thus, not only do non-adherent patients fail to 
benefit from effective medication, they also risk being harmed by less than ideal medication and 
dosage choices). Therefore Healthcare providers need to explain the specific steps of the regimen, 
review the most important details, use written instructions, and encourage their patients to ask 
questions about the regimen for adherence to occur. Also a good amount of information can affect 
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and alter patient’s beliefs about medication especially when it comes to parent’s beliefs about 
height, weight and overall BMI, A connection with other  doctors  including dietitian or a growth 
related problem doctor can be beneficial. For all of the above to be held properly, a 
strong relationship between the doctor and patient will lead to frequent, quality information about 
the patient's disease and better health care for the patient and their family, it also can lessen the 
burden of non-adherence and improve healthcare processes and outcomes for patients.  
 
Limitations 
 
 This study included some limitations, the most important one is the limited number of patients in 
Palestine, as a result, there was a difficulty in sample collection of more than 50 patients as JIA is 
not a common disease. Thus, this study was likely underpowered to detect some of the predicted 
relationships. 
On the other hand, the entire participants in this study were collected, as patients from only one 
specialist doctor that works in the three clinics from which the patients and their proxy were 
interviewed. 
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ي بحث حول مرض التهاب المفاصل 
 
حض  ات السيدات والسادة  المشاركي    بالبحث، أرجو من حض  تكم المشاركة ف
ي كلية الصيدلة جامعة القدس والهدف من الدراسة 
 
الروماتويدي لدى الاطفال والمراهقي   . الباحثة طالبة ماجستي  ف
  . المراهقي   اليومية من جميع نواحيها/هو معرفة مدى تاثي  المرض على حياة الاطفال
ي هذا البحث تطوعية بالكامل وتستطيع الرفض
 
ي سيتم  .مشاركتك ف
هويتك ستبقى مجهولة كما أن البيانات التى
إذا كنت توافق على المشاركة أرجو  .الحصول عليها لن تستخدم إلا لأغراض البحث العلمي  وستحاط بالسرية التامة
 منك الإجابة عن الأسئلة بدقة وموضوعية
 شكرا لتعاونكم
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   -------------------------------------العمر: 
                                         
 : س  جن ال
 ذكر ● 
 انت     ● 
 
 :  مكان السكن
    مدينة ●
 ● قرية 
 مخيم ● 
 
 :  العلاقة الأسرية مع المريض
 م الأ  ●
  بالأ   ●
 آخرون   ●
 
  :   الحالة الاجتماعية
 ● ميى  وج 
 ● أرمل 
 ● أعزب 
 ●مطلق 
 
 :    تعليمي مستوى الال 
 أو أقل  العامةالثانوية  ●
 شهادة الثانوية العامة   ●
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 دبلوم    ●
 شهادة   جامعية ●
 جزء من الجامعة ●
 
 :    السكننوع 
    ملك    ●
 ● إيجار 
 
  :  الدخل الشهري
 0051 أقل من  ●
      0003- 0051 ●
    0005- 0003● 
 0005أكي  من   ●
 
 :   حالة العمل
        ابحث عن عمل  ●
ي (إما خارج المي   ل أو ا  ●
     المي   ل)  من داخل عمل بدوام كامل أو جزئ 
   ربة مي   ل بدوام كامل   ●
ي العمل بسبب الا   ●
 ة   صحيحالتى
 لا أعمل لأسباب أخرى   ●
  
 ---------------------------------- لديك؟ ل يوجد كم طف 
ي كم تبلغ 
 ---------------------------------: العلاج والرعايةتكلفة السفر لتلقى
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Appendix D: Data for results 
 
● Correlating PedsQL and TSQM with sociodemographic outcomes 
 
Table 47: Comparison of parents/ proxy PedsQL in respect with place of residence and age 
groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
physical 
functioning 
City 61.88 29.60 53.13 27.24 60.80 27.75 86.46 15.42 
0.941 
Town 65.28 32.19 53.37 16.38 60.55 24.60 73.88 23.68 
Camp . . . . . . 39.06 15.47 
Emotional 
functioning 
City 70.00 27.61 76.67 18.93 57.73 24.33 76.67 12.58 
0.248 
Town 42.22 22.79 72.50 20.19 62.50 28.78 
100.0
0 
0.00 
Camp . . . . 70.00 . 47.50 24.75 
Social 
functioning 
City 86.00 23.29 65.00 13.23 79.09 17.29 95.00 8.66 
0.798 
Town 81.11 21.91 74.17 20.60 74.38 20.95 90.00 14.14 
Camp . . . . 80.00 . 77.50 10.61 
School 
functioning 
City 70.83 5.89 78.33 16.07 77.50 11.61 63.33 23.09 
0.467 
Town 79.17 22.05 53.61 26.49 76.25 11.88 55.00 14.14 
Camp . . . . 95.00 . 80.00 14.14 
Psychosocial 
City 75.94 23.86 73.33 10.00 70.68 15.23 78.33 10.93 
0.758 
Town 63.12 20.68 66.76 14.12 71.04 16.35 81.67 0.00 
Camp . . . . 81.67 . 68.33 9.43 
Totalpeds 
City 69.96 24.53 66.30 15.22 67.14 18.67 81.16 8.79 
0.996 
Town 63.10 21.74 63.16 14.11 67.39 18.66 79.32 7.72 
Camp . . . . 54.35 .. 58.15 11.53 
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Table 48: Comparison of parents/ proxy PedsQL in respect with place of residence 
 
 
Sum of 
Squares 
df Mean Square F Sig. 
physical functioning 
Between Groups 3576.282 2 1788.141 2.665 
0.080 Within Groups 31531.069 47 670.874 . 
Total 35107.351 49 . . 
Emotional 
functioning 
Between Groups 481.727 2 240.864 .360 
0.700 Within Groups 31480.773 47 669.804 . 
Total 31962.500 49 . . 
Social functioning 
Between Groups 102.015 2 51.008 .140 
0.870 Within Groups 17098.485 47 363.798 . 
Total 17200.500 49 . . 
School functioning 
Between Groups 956.111 2 478.055 1.454 
0.246 Within Groups 12492.670 38 328.754 . 
Total 13448.780 40 . . 
Psychosocial 
Between Groups 340.119 2 170.060 0.645 
0.529 Within Groups 12390.635 47 263.631 . 
Total 12730.755 49 . . 
Totalpeds 
Between Groups 489.894 2 244.947 0.772 
0.468 Within Groups 14919.235 47 317.431 . 
Total 15409.129 49 . . 
 
Table 49: Comparison of parents/proxy TSQM in respect with place of residence and age 
group. 
 
 
Age groups 
Less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Global 
Satisfaction 
City 68.57 23.47 80.95 4.12 53.25 18.73 85.71 14.29 
0.828 Town 57.14 24.74 61.90 13.30 53.27 21.56 75.00 25.25 
Camp . . . . 50.00 . 75.00 15.15 
Effectiveness 
City 73.33 9.94 68.52 13.98 52.53 20.69 74.07 23.13 
0.711 
Town 63.58 28.75 58.33 16.01 65.97 21.71 69.44 19.64 
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Camp . . . . 50.00 . 66.67 15.71 
Side Effects 
City 92.50 16.77 
100.0
0 
0.00 72.16 32.04 100.00 0.00 
0.376 
Town 87.50 25.00 
100.0
0 
0.00 84.38 26.52 68.75 44.19 
Camp . . . . 100.0 . 90.63 13.26 
Convenience 
City 65.56 14.38 59.26 16.97 60.61 15.41 74.07 8.49 
0.940 Town 53.09 27.09 53.70 28.04 59.72 18.96 61.11 0.00 
Camp . . . . 33.33 . 52.78 3.93 
 
Table 50: Comparison of parents/ proxy TSQM in respect with place of residence 
 
 
Sum of 
Squares 
Df Mean Square F Sig. 
Global Satisfaction 
Between Groups 563.427 2 281.714 .632 
0.536 Within Groups 20955.014 47 445.851 . 
Total 21518.441 49 . . 
Effectiveness 
Between Groups 26.431 2 13.215 .030 
0.970 Within Groups 20618.013 47 438.681 . 
Total 20644.444 49 . . 
Side Effects 
Between Groups 310.156 2 155.078 .254 
0.776 Within Groups 28646.094 47 609.491 . 
Total 28956.250 49 . . 
Convenience 
Between Groups 1126.394 2 563.197 1.532 
0.227 Within Groups 17278.545 47 367.629 . 
Total 18404.938 49 . . 
 
Table 51: Children Comparison of PedsQL with place of residence and age groups 
 
 
Age groups  
5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Physical function city 73.44 13.86 71.56 21.72 81.25 15.63 
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town 53.75 24.45 64.58 22.21 67.19 24.31 
0.486 
camp   34.38  64.06 19.89 
Total 62.50 21.88 66.56 22.38 72.32 17.81 
Emotional function 
city 92.50 9.57 77.50 15.14 85.00 10.00 
0.536 town 72.00 17.89 63.33 25.00 60.00 28.28 
camp   50.00  82.50 24.75 
Total 81.11 17.64 69.75 21.06 77.14 20.18 
Social function 
city 72.50 27.54 84.50 20.88 95.00 8.66 
0.642 
town 60.00 27.39 80.00 19.69 85.00 21.21 
camp   60.00  85.00 21.21 
Total 65.56 26.51 81.25 19.99 89.29 14.27 
School function 
city 85.00 12.91 77.50 21.76 78.33 16.07 
0.816 
town 75.00 10.00 75.63 14.99 82.50 10.61 
camp   95.00  85.00 7.07 
Total 80.00 11.95 77.63 18.51 81.43 11.07 
Psychosocial 
Health 
city 83.33 7.20 79.83 15.74 86.11 1.92 
0.650 
town 70.00 13.94 72.13 16.33 75.83 20.03 
camp   68.33  84.17 12.96 
Total 75.93 12.89 75.79 15.73 82.62 10.88 
Total Peds 
city 79.89 3.71 76.96 16.85 84.42 6.55 
0.480 
town 64.35 15.42 69.50 16.23 72.83 21.52 
camp   56.52  77.17 15.37 
Total 71.26 13.83 72.58 16.54 79.04 12.62 
 
● A correlation was completed with respect of the type of relationship between patients and their 
proxy, in which there were 3 choices: mother, father, or other family members.  
 
Table 52: Comparison of parents/ proxy PedsQL in respect with family relationship and 
children age groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
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physical 
functioning 
mother 
60.04 26.64 60.86 32.28 60.49 26.93 66.63 17.77 
0.397 
father 
76.56 33.15 31.25 . 52.50 36.40 93.75 . 
others 
71.88 .00 84.38 . 46.88 . 31.25 4.42 
Emotional 
functioning 
mother 
60.50 28.52 52.86 28.99 57.14 24.31 88.75 16.52 
0.216 
father 
72.50 3.54 50.00 . 75.00 22.91 65.00 . 
others 
62.50 24.75 90.00 . 30.00 . 57.50 38.89 
Social 
functioning 
mother 
86.50 18.27 70.71 23.70 76.79 20.34 87.50 15.00 
0.864 
father 
100.00 .00 55.00 . 81.00 11.94 85.00 . 
others 
70.00 28.28 70.00 . 65.00 . 80.00 7.07 
School 
functioning 
mother 
76.33 25.09 68.33 29.60 77.86 11.88 62.50 20.21 
0.533 
father 
66.67 . 40.00 . 81.25 12.50 50.00 . 
others 
62.50 17.68 90.00 . 65.00 . 65.00 7.07 
psychosocial 
mother 
72.81 19.15 61.15 20.00 70.60 15.26 79.58 3.15 
0.134 
father 
82.78 3.14 48.33 . 77.17 13.94 66.67 . 
others 
65.00 23.57 83.33 . 53.33 . 67.50 8.25 
Totalpeds 
mother 
67.25 18.71 61.81 24.12 67.19 18.08 75.26 7.61 
0.305 father 
80.06 13.05 42.39 . 68.06 19.84 76.09 . 
others 
67.86 15.15 83.70 . 51.09 . 54.89 6.92 
 
Table 53: Comparison of parents/ proxy PedsQL in respect with family relationship and 
children age groups 
 
 
Sum of 
Squares 
df Mean Square F Sig. 
physical functioning 
Between Groups 123.377 2 61.688 0.083 
0.921 Within Groups 34983.974 47 744.340 . 
Total 35107.351 49 . . 
Emotional functioning 
Between Groups 715.992 2 357.996 0.538 
0.587 Within Groups 31246.508 47 664.819 . 
Total 31962.500 49 . . 
Social functioning 
Between Groups 388.873 2 194.437 0.544 
0.584 Within Groups 16811.627 47 357.694 . 
Total 17200.500 49 . . 
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School functioning 
Between Groups 231.717 2 115.858 0.333 
0.719 Within Groups 13217.063 38 347.817 . 
Total 13448.780 40 . . 
Psychosocial 
Between Groups 188.797 2 94.399 0.354 
0.704 Within Groups 12541.957 47 266.850 . 
Total 12730.755 49 . . 
Totalpeds 
Between Groups 106.419 2 53.209 0.163 
0.850 Within Groups 15302.710 47 325.590 . 
Total 15409.129 49 . . 
 
 
Table 54: Comparison of parents/ proxy TSQM in respect with family relationship and 
children age groups 
 
 
Age groups 
Less than 5 5-7 8-12 13-18 
 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Global 
Satisfaction 
mother 
70.00 23.52 60.20 22.91 56.63 21.05 83.93 18.79 
0.892 father 
53.57 15.15 50.00 . 46.67 9.00 71.43 . 
others 
60.71 15.15 78.57 . 35.71 . 71.43 10.10 
Effectivene
ss 
mother 
70.56 25.13 57.14 19.43 62.30 22.66 73.61 21.93 
0.903 father 
77.78 .00 50.00 . 46.67 14.49 66.67 . 
others 
58.33 3.93 55.56 . 50.00 . 72.22 7.86 
Side 
Effects 
mother 
90.00 21.89 92.86 18.90 77.68 26.71 84.38 31.25 
0.145 
father 100.0
0 
0.00 
100.0
0 
. 95.00 11.18 100.00 . 
others 100.0
0 
0.00 
100.0
0 
. 6.25 . 90.63 13.26 
Convenien
ce 
mother 
66.11 25.99 54.76 22.78 61.90 18.60 61.11 4.54 
0.460 father 
58.33 19.64 16.67 . 53.33 12.17 72.22 . 
others 
55.56 15.71 55.56 . 44.44 . 47.22 3.93 
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Table 55: Comparison of parents/ proxy TSQM in respect with family relationship and 
children age groups 
 
 Sum of Squares df Mean Square F Sig. 
Global Satisfaction 
Between Groups 1214.133 2 607.067 1.405 
0.255 Within Groups 20304.308 47 432.007 . 
Total 21518.441 49 . . 
Effectiveness 
Between Groups 569.391 2 284.695 0.667 
0.518 Within Groups 20075.054 47 427.129 . 
Total 20644.444 49 . . 
Side Effects 
Between Groups 1275.694 2 637.847 1.083 
0.347 Within Groups 27680.556 47 588.948 . 
Total 28956.250 49 . . 
Convenience 
Between Groups 1003.753 2 501.876 1.356 
0.268 Within Groups 17401.186 47 370.238 . 
Total 18404.938 49 . . 
 
• A correlation evaluated PedsQL or TSQM scores and JIA subtypes. 
 
Table 56: Compression between PedsQL with JIA subtypes 
 
 JIA subtypes N Mean 
Standard 
deviation 
Sig 
physical functioning 
Oligoarthritis 24 68.6074 24.93469 
0.148 
Systematicarthritis 14 58.8967 26.38637 
Polyarticular arthritis 7 41.0714 15.35481 
JIA 3 46.8750 42.27422 
Erthesities related arthritis 2 59.3750 44.19417 
Emotional functioning 
Oligoarthritis 24 63.9583 24.62674 
0.888 Systematicarthritis 14 60.7143 25.02746 
Polyarticular arthritis 7 55.7143 29.92053 
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JIA 3 73.3333 25.16611 
Erthesities related arthritis 2 65.0000 49.49747 
Social functioning 
Oligoarthritis 24 82.7083 17.75309 
0.563 
Systematicarthritis 14 79.2857 19.88981 
Polyarticular arthritis 7 70.7143 23.70453 
JIA 3 70.0000 13.22876 
Erthesities related arthritis 2 82.5000 3.53553 
School functioning 
Oligoarthritis 20 71.0000 22.74573 
0.841 
Systematicarthritis 11 73.1818 13.28020 
Polyarticular arthritis 5 69.0000 15.96872 
JIA 3 83.3333 12.58306 
Erthesities related arthritis 2 67.5000 3.53553 
Psychococial 
Oligoarthritis 24 71.7361 16.04690 
0.848 
Systematicarthritis 14 70.5952 16.47138 
Polyarticular arthritis 7 64.4048 19.35723 
JIA 3 75.5556 15.12295 
Erthesities related arthritis 2 71.6667 14.14214 
Totalpeds 
Oligoarthritis 24 70.7162 17.81418 
0.404 
Systematicarthritis 14 66.4074 17.39609 
Polyarticular arthritis 7 55.3744 16.31281 
JIA 3 65.5797 18.52084 
Erthesities related arthritis 2 67.3913 24.59502 
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Table57: compression between TSQM with JIA subtypes 
 
 JIA subtypes N Mean Standard deviation Sig 
Global Satisfaction 
Oligoarthritis 24 62.2024 21.52970 
0.278 
Systematicarthritis 14 55.9529 18.76446 
Polyarticular arthritis 7 72.4490 24.54642 
JIA 3 50.0000 0.00000 
Erthesities related arthitis 2 78.5714 20.20305 
Effectiveness 
Oligoarthritis 24 64.5833 23.27301 
0.082 
Systematicarthritis 14 53.9683 15.92787 
Polyarticular arthritis 7 75.3968 14.29306 
JIA 3 50.0000 11.11111 
Erthesities related arthitis 2 80.5556 3.92837 
Side Effects 
Oligoarthritis 24 88.2813 26.14969 
0.594 
Systematicarthritis 14 89.2857 18.41505 
Polyarticular arthritis 7 83.9286 29.50484 
JIA 3 87.5000 21.65064 
Erthesities related arthitis 2 59.3750 30.93592 
Convenience 
Oligoarthritis 24 65.2778 21.62544 
0.226 
Systematicarthritis 14 51.9841 17.10355 
Polyarticular arthritis 7 54.7619 13.39053 
JIA 3 48.1481 16.97250 
Erthesities related arthitis 2 55.5556 7.85674 
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● Economic outcomes 
Correlation of PedsQL or TSQM with parent’s education level, type of house, parent’s monthly 
income, parents work status, and the cost of transportation, each of which were analyzed with 
taking in count children’s age groups as next: less than 5, from 5 to 7, from 8 to 12, and from 13 
to 18, and at the same time each one of them were also analyzed without children’s age groups. 
• First, for parent’s education level with the following choices: high school or less, diploma, 
and university 
 
Table 58: Comparison of parents/ proxy PedsQL in respect with parent’s level of education 
and children age groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
sig 
physical 
functioning 
less 
secondary 53.01 20.93 65.80 34.78 54.17 24.66 55.80 25.53 
0.428 
secondary 
58.04 14.96 53.13 30.94 43.13 36.20 . . 
Diploma 
18.75 . . . . . 93.75 . 
university 
86.88 14.22 40.63 . 75.52 19.51 50.00 . 
Emotional 
functioning 
less 
secondary 65.00 27.99 60.83 34.27 58.33 27.27 81.00 29.24 
0.879 
Secondary 
76.25 23.23 45.00 7.07 55.00 26.46 . . 
Diploma 
25.00 . . . . . 65.00 . 
University 
57.00 21.68 55.00 . 67.50 23.18 65.00 . 
Social 
functioning 
less 
secondary 93.75 12.50 75.83 23.11 74.44 20.98 88.00 11.51 
0.287 
Secondary 
82.50 22.55 57.50 3.54 80.00 20.31 . . 
Diploma 
45.00 . . . . . 85.00 . 
University 
91.00 12.45 50.00 . 79.17 13.20 70.00 . 
School 
functioning 
less 
secondary 77.50 3.54 69.33 30.38 73.75 11.88 58.00 10.37 
0.079 
Secondary 
42.50 10.61 40.00 . 81.00 12.94 . . 
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Diploma 
. . . . . . 50.00 . 
University 
83.33 15.21 85.00 . 80.83 11.14 90.00 . 
Psychosoci
al 
less 
secondary 78.13 10.68 66.34 22.81 68.06 16.41 75.67 8.55 
0.393 
Secondary 
75.42 21.74 49.17 1.18 72.00 17.61 . . 
Diploma 
35.00 . . . . . 66.67 . 
University 
74.89 14.46 63.33 . 75.83 11.73 75.00 . 
Totalpeds 
less 
secondary 68.05 14.51 66.93 27.45 62.93 19.16 68.90 13.86 
0.442 Secondary 
67.63 11.11 50.88 12.01 62.26 19.39 . . 
Diploma 
27.78 . . . . . 76.09 . 
University 
79.56 11.80 55.43 . 75.72 13.61 66.30 . 
 
Table 59: Comparison of parents/proxy pedsQL in respect with parent’s level of education 
 
 
Sum of 
Squares 
df Mean Square F Sig. 
physical functioning 
Between Groups 4247.272 3 1415.757 2.110 
0.112 Within Groups 30860.078 46 670.871 . 
Total 35107.351 49 . . 
Emotional functioning 
Between Groups 766.863 3 255.621 .377 
0.770 Within Groups 31195.637 46 678.166 . 
Total 31962.500 49 . . 
Social functioning 
Between Groups 561.223 3 187.074 .517 
0.673 Within Groups 16639.277 46 361.723 . 
Total 17200.500 49 . . 
School functioning 
Between Groups 2312.345 3 770.782 2.561 
0.070 Within Groups 11136.435 37 300.985 . 
Total 13448.780 40 . . 
Psychosocial 
Between Groups 1000.651 3 333.550 1.308 
0.283 Within Groups 11730.103 46 255.002 . 
Total 12730.755 49 . . 
Totalpeds 
Between Groups 1550.180 3 516.727 1.715 
0.177 Within Groups 13858.949 46 301.282 . 
Total 15409.129 49 . . 
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Table 60: Comparison of parents/ proxy TSQM in respect with parent’s level of education 
and children age groups 
 
 
Age groups 
Less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
sig 
Global 
Satisfaction 
less 
secondary 66.07 15.84 64.29 18.63 53.70 20.83 78.57 18.21 
0.557 Secondary 
69.64 17.86 39.29 15.15 61.43 21.78 . . 
Diploma 
92.86 . . . . . 71.43 . 
University 
58.57 28.30 85.71 . 45.24 11.66 85.71 . 
Effectiveness 
less 
secondary 65.28 25.41 56.48 14.24 60.49 20.87 76.67 16.85 
0.437 Secondary 
75.00 9.62 41.67 11.79 63.33 25.03 . . 
Diploma 
77.78 . . . . . 66.67 . 
University 
67.78 30.02 83.33 . 49.07 19.06 55.56 . 
Side Effects 
less 
secondary 
100.0
0 
.00 
100.0
0 
.00 81.25 26.52 83.75 27.10 
0.935 
Secondary 100.0
0 
.00 75.00 35.36 86.25 18.96 . . 
Diploma 
62.50 . . . . . 100.00 . 
University 
87.50 27.95 
100.0
0 
. 67.71 40.58 100.00 . 
Convenience 
less 
secondary 68.06 20.97 57.41 14.77 58.64 17.37 56.67 9.13 
0.231 Secondary 
75.00 23.35 16.67 .00 57.78 25.64 . . 
Diploma 
61.11 . . . . . 72.22 . 
University 
51.11 25.58 77.78 . 60.19 10.19 55.56 . 
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Table 61: Comparison of parents/ proxy TSQM in respect with parent’s level of education 
 
 
Sum of 
Squares 
df Mean Square F Sig. 
Global Satisfaction 
Between Groups 1278.984 3 426.328 .969 
0.416 Within Groups 20239.458 46 439.988 . 
Total 21518.441 49 . . 
Effectiveness 
Between Groups 352.628 3 117.543 .266 
0.849 Within Groups 20291.816 46 441.126 . 
Total 20644.444 49 . . 
Side Effects 
Between Groups 862.209 3 287.403 .471 
0.704 Within Groups 28094.041 46 610.740 . 
Total 28956.250 49 . . 
Convenience 
Between Groups 205.197 3 68.399 .173 
0.914 Within Groups 18199.741 46 395.647 . 
Total 18404.938 49 . . 
 
• Second correlation was with the type of house the family live in with choices of: family 
own house, or by rent house. 
 
Table 62: Comparison of parents/ proxy PedsQL in respect with type of house and children 
age groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
physical 
functioning 
own 
64.09 24.94 
62.6
3 
32.18 58.27 27.31 60.40 25.60 
0.245 
Rent 
. . 
40.6
3 
. 55.21 39.57 . . 
own 
62.50 25.10 
56.8
8 
29.99 63.24 25.55 76.43 25.12 
0.895 
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Emotional 
functioning 
rent 
. . 
55.0
0 
. 43.33 15.28 . . 
Social 
functioning 
own 
86.07 19.03 
71.2
5 
21.34 78.82 15.96 85.00 11.55 
0.479 
rent 
. . 
50.0
0 
. 68.33 30.14 . . 
School 
functioning 
own 
71.67 21.16 
64.4
4 
29.70 77.94 12.51 61.43 15.47 
0.384 
rent 
. . 
85.0
0 
. 77.50 3.54 . . 
Psychosoci
al 
own 
73.12 17.94 
62.0
5 
20.86 73.33 14.53 74.29 7.75 
0.882 
rent 
. . 
63.3
3 
. 60.28 15.69 . . 
Totalpeds 
own 
69.16 17.16 
62.9
2 
24.78 68.18 16.92 69.56 11.72 
0.531 
rent 
. . 
55.4
3 
. 57.63 24.67 . . 
 
Table 63: Correlation of parents/ proxy PedsQL in respect to type of house 
 
 house kind N Mean Std. Deviation T df Sig. 
physical functioning 
Own 46 61.1251 26.44904 .682 48 
0.499 
Rent 4 51.5625 33.12107 . . 
Emotional functioning 
Own 46 63.9130 25.92539 1.337 48 
0.187 
Rent 4 46.2500 13.76893 . . 
Social functioning 
Own 46 80.6522 17.68894 1.768 48 
0.083 
Rent 4 63.7500 26.25992 . . 
School functioning 
Own 38 71.4474 18.88471 -.774 39 
0.444 
Rent 3 80.0000 5.00000 . . 
Psychosocial 
Own 46 71.4493 16.21591 1.246 48 0.219 
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Rent 4 61.0417 12.89873 . . 
Totalpeds 
Own 46 67.7764 17.49115 1.161 48 
0.251 
Rent 4 57.0803 20.17254 . . 
 
Table 64: Comparison of parents/ proxy TSQM in respect with type of house and children 
age groups 
 
 
Age groups 
Less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Global 
Satisfaction 
own 
66.33 21.42 58.04 20.36 54.90 19.35 78.57 15.43 0.108 
rent 
. . 85.71 . 42.86 14.29 . . 
Effectiveness 
own 
69.84 21.65 52.78 14.55 57.52 22.82 72.22 16.04 0.514 
rent 
. . 83.33 . 59.26 8.49 . . 
Side Effects 
own 
92.86 18.81 93.75 17.68 79.04 28.03 88.39 23.50 0.589 
rent 
. . 100.00 . 75.00 43.30 . . 
Convenience 
own 
63.49 23.13 47.22 22.62 60.78 17.40 58.73 9.55 0.076 
rent 
. . 77.78 . 48.15 12.83 . . 
 
Table 65: Comparison of parents/ proxy TSQM in respect with type of house 
 
 
House type N Mean Std. Deviation T df Sig. 
Global Satisfaction 
own 46 62.5260 20.78335 .817 48 
0.418 
rent 4 53.5714 24.39750 . . 
Effectiveness 
own 46 62.6812 21.10341 -.240 48 
0.811 
rent 4 65.2778 13.88889 . . 
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Side Effects 
own 46 87.2283 23.38374 .468 48 
0.642 
rent 4 81.2500 37.50000 . . 
Convenience 
own 46 58.9372 19.64982 .332 48 
0.742 
rent 4 55.5556 18.14437 . . 
 
• Third correlation was with family monthly income (that was split to five choices: less than 
1500 NIS, from 1500-3000 NIS, from 3000-5000 NIS, and no income).  
 
Table 66: Comparison of parents/ proxy PedsQL in respect with monthly income and 
children age groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
physical 
functioning 
less  1500 45.68 26.57 62.85 18.76 45.63 31.22 31.25 4.42 
0.859 
1500-3000 71.88 18.75 59.38 46.00 63.75 24.67 72.17 17.00 
3000-5000 61.43 29.08 57.81 24.31 65.18 32.90 . . 
more than 
5000 
85.94 19.89 . . 50.00 . 71.88 30.94 
none 65.63 . . . 51.56 28.73 . . 
Emotional 
functioning 
less  1500 65.00 35.00 75.00 25.98 53.00 23.35 57.50 38.89 
0.374 
1500-3000 58.33 12.58 47.50 33.29 55.00 29.15 96.67 5.77 
3000-5000 60.00 25.98 47.50 10.61 72.86 17.29 . . 
more than 
5000 
52.50 31.82 . . 50.00 . 65.00 . 
none 
100.0
0 
. . . 52.50 53.03 . . 
Social 
functioning 
less  1500 70.00 22.91 66.67 20.21 73.00 24.65 80.00 7.07 
0.531 
1500-3000 83.33 28.87 77.50 25.98 78.00 16.05 93.33 11.55 
3000-5000 96.00 6.52 55.00 7.07 83.57 15.20 . . 
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more than 
5000 
85.00 21.21 . . 55.00 . 77.50 10.61 
none 95.00 . . . 75.00 21.21 . . 
School 
functioning 
less  1500 75.00 . 60.56 38.74 81.25 12.50 65.00 7.07 
0.927 
1500-3000 75.00 35.36 68.33 25.66 77.00 12.55 53.33 10.41 
3000-5000 68.89 29.92 85.00 . 81.43 12.15 . . 
more than 
5000 
66.67 . . . 70.00 . 70.00 28.28 
none . . . . 65.00 . . . 
Psychosoci
al 
less  1500 65.56 26.48 67.41 14.49 67.17 18.02 67.50 8.25 
0.786 
1500-3000 73.33 21.67 61.04 28.23 70.00 18.10 81.11 20.96 
3000-5000 75.78 10.66 56.67 9.43 79.29 6.73 . . 
more than 
5000 
65.28 21.61 . . 58.33 . 70.83 5.89 
none 97.50 . . . 64.17 24.75 . . 
Totalpeds 
less  1500 58.47 27.00 67.58 15.30 59.45 21.60 54.89 6.92 
0.760 
1500-3000 71.63 14.90 60.31 35.23 67.83 20.14 18.24 5.77 
3000-5000 69.14 14.74 57.40 2.79 74.38 12.94 . . 
more than 
5000 
74.50 20.90 . . 55.43 . 71.20 6.92 
none 83.33 . . . 59.78 26.13 . . 
 
Table 67: Comparison of parents/ proxy PedsQL in respect with monthly income 
 
 
Sum of 
Squares 
df Mean Square F Sig. 
physical functioning 
Between Groups 3590.030 4 897.508 1.281 
0.291 Within Groups 31517.320 45 700.385 . 
Total 35107.351 49 . . 
Emotional functioning 
Between Groups 333.388 4 83.347 0.119 
0.975 Within Groups 31629.112 45 702.869 . 
Total 31962.500 49 . . 
Social functioning 
Between Groups 1187.982 4 296.995 0.835 
0.510 Within Groups 16012.518 45 355.834 . 
Total 17200.500 49 . . 
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School functioning 
Between Groups 673.392 4 168.348 0.474 
0.754 Within Groups 12775.389 36 354.872 . 
Total 13448.780 40 . . 
Psychosocial 
Between Groups 591.484 4 147.871 0.548 
0.701 Within Groups 12139.271 45 269.762 . 
Total 12730.755 49 . . 
Totalpeds 
Between Groups 770.187 4 192.547 0.592 
0.670 Within Groups 14638.942 45 325.310 . 
Total 15409.129 49 . . 
 
Table 68: Comparison of parents/proxy TSQM in respect with monthly income and 
children age groups 
 
 
Age groups 
Less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Global 
Satisfaction 
less  
1500 
71.43 21.43 69.05 16.50 57.14 26.24 71.43 10.10 
0.606 
1500
-
3000 
42.86 28.57 57.14 19.34 61.43 23.47 83.33 22.96 
3000
-
5000 
68.57 11.96 57.14 40.41 44.56 10.26 .. .. 
more 
than 
5000 
75.00 15.15 .. .. 50.00 .. 78.57 10.10 
none 92.86 .. .. .. 53.57 15.15 .. .. 
Effectiveness 
less  
1500 
57.41 19.51 62.96 12.83 65.56 20.56 72.22 7.86 
0.142 1500
-
3000 
53.70 28.51 50.00 12.00 67.78 20.93 79.63 22.45 
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3000
-
5000 
81.11 19.48 58.33 35.36 49.21 23.45 .. .. 
more 
than 
5000 
80.56 3.93 .. .. 38.89 .. 61.11 7.86 
none 77.78 .. .. .. 52.78 3.93 .. .. 
Side Effects 
less  
1500 
87.50 21.65 
100.0
0 
 73.75 30.75 90.63 13.26 
0.974 
1500
-
3000 
100.00  
100.0
0 
 75.00 40.75 79.17 36.08 
3000
-
5000 
100.00 .. 75.00 35.36 86.61 26.13 .. .. 
more 
than 
5000 
68.75 44.19 .. .. 62.50 .. 
100.0
0 
0.00 
none 100.00    78.13 30.94   
Convenience 
less  
1500 
57.41 11.56 51.85 11.56 61.11 24.22 47.22 3.93 
0.435 
1500
-
3000 
57.41 13.98 51.39 27.36 64.44 22.43 62.96 3.21 
3000
-
5000 
81.11 16.01 47.22 43.21 56.35 11.31 .. .. 
more 
than 
5000 
27.78 23.57 .. .. 44.44 .. 63.89 11.79 
none 83.33    55.56    
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Table 69: Comparison of parents/ proxy TSQM in respect with monthly income 
 
 
Sum of 
Squares 
df Mean Square F Sig. 
Global Satisfaction 
Between Groups 1372.701 4 343.175 .767 
0.553 Within Groups 20145.740 45 447.683 . 
Total 21518.441 49 . . 
Effectiveness 
Between Groups 55.605 4 13.901 .030 
0.998 Within Groups 20588.839 45 457.530 . 
Total 20644.444 49 . . 
Side Effects 
Between Groups 383.977 4 95.994 .151 
0.962 Within Groups 28572.273 45 634.939 . 
Total 28956.250 49 . . 
Convenience 
Between Groups 1453.609 4 363.402 .965 
0.436 Within Groups 16951.330 45 376.696 . 
Total 18404.938 49 . . 
 
 
• Forth correlation was with parents working status; options provided were as follows: 
Searching for Work, Working full or part time, full time house keeper, or not working for 
other reasons. 
 
Table 70: Comparison of parents/ proxy PedsQL in respect with work status and children 
age groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviatio
n 
Mean 
Standard 
Deviation 
Sig. 
physical 
functioning 
Searching 
71.88 . 79.69 6.63 25.00 . 50.00 . 0.754 
part timer 
84.38 27.06 46.88 47.29 63.89 30.90 93.75 . 
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house 
keeper 57.23 23.22 63.89 29.36 55.63 25.80 62.72 23.45 
not 
working 
for other 
reasons 
. . 50.00 . . . 28.13 . 
Emotional 
functioning 
Searching 
30.00 . 65.00 35.36 40.00 . 65.00 . 
0.404 
part timer 
61.67 18.93 38.33 34.03 65.00 27.27 65.00 . 
house 
keeper 66.00 26.44 73.33 17.56 58.00 24.29 93.75 7.50 
not 
working 
for other 
reasons 
. . 45.00 . . . 30.00 . 
Social 
functioning 
Searching 
70.00 . 65.00 7.07 65.00 . 70.00 . 
0.858 
part timer 
98.33 2.89 70.00 25.98 81.11 13.64 85.00 . 
house 
keeper 84.00 20.92 78.33 25.66 75.00 21.98 88.75 13.15 
not 
working 
for other 
reasons 
. . 45.00 . . . 85.00 . 
School 
functioning 
Searching 
. . 90.00 . . . 90.00 . 
0.980 
part timer 
79.17 17.68 57.50 24.75 77.78 12.02 50.00 . 
house 
keeper 69.17 23.11 63.89 40.97 78.00 12.29 55.00 9.13 
not 
working 
for other 
reasons 
. . 75.00 . . . 70.00 . 
Psychosocial 
Searching 
50.00 . 66.67 23.57 52.50 . 75.00 . 
0.844 
part timer 
80.37 4.72 51.94 26.44 74.63 14.36 66.67 . 
house 
keeper 73.25 19.58 71.85 14.28 70.33 15.61 79.17 3.97 
not 
working . . 55.00 . . . 61.67 . 
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for other 
reasons 
Totalpeds 
Searching 
59.72 . 71.54 17.20 40.28 . 66.30 . 
0.874 
part timer 
81.15 9.42 49.98 34.95 70.89 17.18 76.09 . 
house 
keeper 66.51 18.44 70.84 18.46 65.37 17.78 73.63 10.36 
not 
working 
for other 
reasons 
. . 53.26 . . . 50.00 . 
 
Table 71: Comparison of parents/ proxy PedsQL in respect with work status 
 
 
Sum of 
Squares 
Df Mean Square F Sig. 
physical functioning 
Between Groups 1623.178 3 541.059 0.743 
0.532 Within Groups 33484.173 46 727.917 . 
Total 35107.351 49 . . 
Emotional functioning 
Between Groups 2663.287 3 887.762 1.394 
0.257 Within Groups 29299.213 46 636.939 . 
Total 31962.500 49 . . 
Social functioning 
Between Groups 1385.315 3 461.772 1.343 
0.272 Within Groups 15815.185 46 343.808 . 
Total 17200.500 49 . . 
School functioning 
Between Groups 770.891 3 256.964 0.750 
0.529 Within Groups 12677.890 37 342.646 . 
Total 13448.780 40 . . 
Psychosocial 
Between Groups 800.256 3 266.752 1.029 
0.389 Within Groups 11930.498 46 259.359 . 
Total 12730.755 49 . . 
Totalpeds 
Between Groups 692.847 3 230.949 0.722 
0.544 Within Groups 14716.282 46 319.919 . 
Total 15409.129 49 . . 
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• Fifth comparison investigated the number of family members; (with options offered being 
families less than 5 members, between 5-7 members, and more than 8 members). 
 
Table 72: Comparison of parents/ proxy PedsQL in respect with family member number 
and children age groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
physical 
functioning 
less 
than 5 65.33 29.34 50.00 30.86 
55.3
1 
26.40 
51.5
6 
24.31 
0.654 
5-7 
72.92 7.86 63.89 29.36 
58.9
3 
33.29 
63.9
3 
27.95 
more 
than8 45.31 11.05 
100.0
0 
. 
63.5
4 
31.61 . . 
Emotional 
functioning 
less 
than 5 56.67 26.93 45.00 32.02 
53.0
0 
26.79 
87.5
0 
3.54 
0.332 
5-7 
73.33 27.54 73.33 17.56 
72.8
6 
17.29 
72.0
0 
29.28 
more 
than8 72.50 3.54 65.00 . 
55.0
0 
31.22 . . 
Social 
functioning 
less 
than 5 84.44 18.45 57.00 9.08 
70.5
0 
18.63 
87.5
0 
17.68 
0.199 
5-7 
81.67 27.54 78.33 25.66 
82.8
6 
15.24 
84.0
0 
10.84 
more 
than8 
100.0
0 
.00 
100.0
0 
. 
86.6
7 
18.93 . . 
School 
functioning 
less 
than 5 73.89 22.65 68.33 25.66 
77.5
0 
11.12 
55.0
0 
7.07 
0.942 
5-7 
65.00 21.21 63.89 40.97 
77.5
0 
13.69 
64.0
0 
17.82 
more 
than8 . . 75.00 . 
80.0
0 
15.00 . . 
Psychosocial 
less 
than 5 68.92 17.06 52.83 20.03 
67.0
0 
15.09 
76.6
7 
4.71 
0.289 
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5-7 
76.94 25.55 71.85 14.28 
76.5
5 
13.27 
73.3
3 
8.98 
more 
than8 86.25 1.77 80.00 . 
73.8
9 
20.02 . . 
Totalpeds 
less 
than 5 67.56 20.09 51.63 23.52 
63.0
9 
17.51 
67.9
3 
11.53 
0.572 5-7 
74.72 15.23 70.84 18.46 
70.0
4 
18.36 
70.2
1 
13.08 
more 
than8 68.06 3.93 88.10 . 
70.2
9 
22.91 . . 
 
Table 73: Comparison of parents/ proxy TSQM in respect with family member number 
and children age groups 
 
 
Age groups 
Less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviatio
n 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviatio
n 
Mean 
Standard 
Deviation 
Sig. 
Global 
Satisfaction 
less 
than 
5 
65.08 24.08 57.14 21.43 
47.8
6 
11.69 89.29 15.15 
0.320 
5-7 
78.57 12.37 73.81 20.62 
56.8
0 
21.05 74.29 14.81 
more 
than8 53.57 15.15 42.86 . 
61.9
0 
33.76 . . 
Effectivene
ss 
less 
than 
5 
69.75 25.78 50.00 18.43 
53.8
9 
18.15 83.33 23.57 
0.798 
5-7 
62.96 13.98 64.81 16.04 
56.3
5 
23.45 67.78 12.67 
more 
than8 80.56 3.93 61.11 . 
74.0
7 
25.05 . . 
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Side 
Effects 
less 
than 
5 
88.89 22.92 90.00 22.36 
68.7
5 
26.84 
100.0
0 
. 
0.328 
5-7 100.0
0 
.00 
100.0
0 
.00 
96.4
3 
9.45 83.75 27.10 
more 
than8 
100.0
0 
.00 
100.0
0 
. 
68.7
5 
54.13 . . 
Convenien
ce 
less 
than 
5 
61.73 27.42 40.00 21.66 
56.1
1 
11.55 55.56 15.71 
0.613 
5-7 
62.96 19.51 66.67 24.22 
59.5
2 
19.96 60.00 8.24 
more 
than8 72.22 .00 55.56 . 
66.6
7 
29.40 . . 
 
Table 74: Comparison of parents/ proxy TSQM in respect with family member numbers 
 
 
Sum of 
Squares 
Df Mean Square F Sig. 
Global Satisfaction 
Between Groups 1159.969 2 579.985 1.339 
0.272 Within Groups 20358.472 47 433.159 . 
Total 21518.441 49 . . 
Effectiveness 
Between Groups 866.825 2 433.412 1.030 
0.365 Within Groups 19777.619 47 420.800 . 
Total 20644.444 49 . . 
Side Effects 
Between Groups 1541.052 2 770.526 1.321 
0.277 Within Groups 27415.198 47 583.302 . 
Total 28956.250 49 . . 
Convenience 
Between Groups 886.473 2 443.236 1.189 
0.313 Within Groups 17518.466 47 372.733 . 
Total 18404.938 49 . . 
 
 
• Sixth comparison was with respect to transportation cost; (with cost range offered as less 
than 100 NIS, from 100-400 NIS, more than 400 NIS, and transportation by the use of 
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family own car). 
 
Table 75: Comparison of parents/ proxy PedsQL in respect with cost of transportation and 
children age groups 
 
 
Age groups  
less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
physical 
functioning 
less 
than 
100 
73.21 16.78 96.88 . 55.21 17.77 65.92 21.69 
0.530 
100-
400 59.32 25.80 62.85 18.76 66.19 26.44 34.38 . 
more 
than 
400 
51.56 28.73 68.75 34.80 41.41 41.57 28.13 . 
own 
car 
100.0
0 
. 25.00 22.10 48.44 15.47 81.25 17.68 
Emotional 
functioning 
less 
than 
100 
63.33 20.21 75.00 . 51.67 22.55 88.33 20.21 
0.752 
100-
400 63.13 28.02 75.00 25.98 65.91 28.79 85.00 . 
more 
than 
400 
52.50 38.89 51.67 12.58 58.75 10.31 30.00 . 
own 
car 75.00 . 27.50 38.89 45.00 35.36 77.50 17.68 
Social 
functioning 
less 
than 
100 
78.33 25.66 
100.0
0 
. 63.33 28.43 83.33 15.28 
0.583 
100-
400 85.00 20.00 66.67 20.21 79.55 15.88 75.00 . 
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more 
than 
400 
95.00 7.07 71.67 24.66 86.25 17.02 85.00 . 
own 
car 
100.0
0 
. 52.50 3.54 67.50 3.54 92.50 10.61 
School 
functioning 
less 
than 
100 
61.67 34.03 90.00 . 76.67 5.77 66.67 22.55 
0.744 
100-
400 82.22 8.55 60.56 38.74 77.50 13.39 60.00 . 
more 
than 
400 
75.00 . 57.50 24.75 80.00 12.91 70.00 . 
my 
car 66.67 . 85.00 . 77.50 17.68 50.00 . 
Psychosoci
al 
less 
than 
100 
67.78 19.17 88.33 . 63.89 17.35 79.44 3.85 
0.707 
100-
400 74.44 21.08 67.41 14.49 73.56 16.58 73.33 . 
more 
than 
400 
72.08 13.55 59.44 17.82 75.00 8.05 61.67 . 
own 
car 80.56 . 45.42 25.34 63.33 18.86 73.33 9.43 
Totalpeds 
less 
than 
100 
69.61 15.46 91.30 . 60.87 17.49 74.98 9.29 
0.596 
100-
400 67.88 18.59 67.58 15.30 70.76 20.03 59.78 . 
more 
than 
400 
63.59 21.19 63.29 23.10 63.70 15.04 50.00 . 
own 
car 89.29 . 37.44 25.45 58.15 17.68 76.09 . 
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Table 76: Comparison of parents/ proxy PedsQL in respect with cost of transportation 
 
 Sum of Squares Df Mean Square F Sig. 
physical functioning 
Between Groups 
1677.080 3 559.027 0.769 
0.517 
Within Groups 
33430.271 46 726.745 . 
Total 
35107.351 49 . . 
Emotional functioning 
Between Groups 
2374.829 3 791.610 1.231 
0.309 
Within Groups 
29587.671 46 643.210 . 
Total 
31962.500 49 . . 
Social functioning 
Between Groups 
339.848 3 113.283 0.309 
0.819 
Within Groups 
16860.652 46 366.536 . 
Total 
17200.500 49 . . 
School functioning 
Between Groups 
222.250 3 74.083 0.207 
0.891 
Within Groups 
13226.531 37 357.474 . 
Total 
13448.780 40 . . 
Psychosocial 
Between Groups 
560.606 3 186.869 0.706 
0.553 
Within Groups 
12170.149 46 264.568 . 
Total 
12730.755 49 . . 
Totalpeds 
Between Groups 
642.406 3 214.135 0.667 
0.577 
Within Groups 
14766.723 46 321.016 . 
Total 
15409.129 49 . . 
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Table 77: Comparison of parents/ proxy TSQM in respect with cost of transportation and 
children age groups 
 
 
Age groups 
Less than 5 5-7 8-12 13-18  
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Sig. 
Global 
Satisfaction 
Less 
than 
100 
45.24 28.87 85.71 . 37.30 11.25 78.57 18.90 
0.781 
100-400 
75.00 16.64 69.05 16.50 58.44 22.99 78.57 . 
More 
than 
400 
64.29 20.20 40.48 10.91 48.21 3.57 64.29 . 
Own 
car 64.29 . 67.86 25.25 57.14 .00 85.71 20.20 
Effectiveness 
Less 
than 
100 
53.70 28.51 55.56 . 42.59 22.45 64.81 16.04 
0.999 
100-400 
73.61 19.64 62.96 12.83 61.11 24.72 66.67 . 
More 
than 
400 
75.00 27.50 48.15 13.98 55.56 6.42 77.78 . 
own car 
77.78 . 58.33 35.36 66.67 15.71 83.33 23.57 
Side Effects 
Less 
than 
100 
100.0
0 
.00 
100.0
0 
. 54.17 26.02 79.17 36.08 
0.987 
100-400 
87.50 24.09 
100.0
0 
.00 81.25 34.00 100.00 . 
More 
than 
400 
100.0
0 
.00 83.33 28.87 85.94 16.44 81.25 . 
own car 100.0
0 
. 
100.0
0 
.00 84.38 22.10 100.00 .00 
Convenience 
Less 
than 
100 
66.67 29.40 83.33 . 44.44 11.11 59.26 3.21 0.307 
100-400 
60.42 23.28 51.85 11.56 65.15 18.27 44.44 . 
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More 
than 
400 
80.56 19.64 29.63 22.45 51.39 12.32 50.00 . 
own car 
44.44 . 63.89 19.64 61.11 15.71 69.44 3.93 
 
Table 78: Comparison of parents/ proxy TSQM in respect with cost of transportation 
 
TSQM domains  
Sum of Squares Df Mean Square F Sig. 
Global Satisfaction 
Between Groups 
2370.891 3 790.297 1.899 
0.143 
Within Groups 
19147.550 46 416.251 . 
Total 
21518.441 49 . . 
Effectiveness 
Between Groups 
1563.047 3 521.016 1.256 
0.301 
Within Groups 
19081.397 46 414.813 . 
Total 
20644.444 49 . . 
Side Effects 
Between Groups 
1001.669 3 333.890 0.549 
0.651 
Within Groups 
27954.581 46 607.708 . 
Total 
28956.250 49 . . 
Convenience 
Between Groups 
848.961 3 282.987 0.741 
0.533 
Within Groups 
17555.977 46 381.652 . 
Total 
18404.938 49 . . 
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 للاطفال  دى المرضى الفلسطينيين المصابين بالتهاب المفاصل مجهول السببل  الرضا العلاجي  للدواءو  الحياة عیةون متقیی
  ربى محمود عبد جعافرةاد: داع
  حلاق نر حسیوكتداف: الراش
 صالملخ
 
دراسة هذه الامراض واعراضها على حياة المريض يمكن أن تؤثر الأمراض المزمنة على حياة المريض بطريقة سلبية للغاية؛ وتعد 
 من الاشياء المهمة والضرورية. 
هو أحد الأمراض الالتهابية المزمنة التي تؤثر على المفاصل في جميع أنحاء الجسم ,  للاطفال التهاب المفاصل مجهول السبب
  .وتؤدي إلى العديد من الأحداث السلبية غير المرغوب فيها
أو تأثيرها على الأطفال، ومن هذه النقطة كان الهدف من  التهاب المفاصل مجهول السببجد دراسات حول في فلسطين، لا تو 
رضاهم عن العلاج الذي يتلقونه، بالإضافة إلى قياس بعض العوامل  تقييم مدىنوعية حياة الأطفال وكذلك  تقييمهذه الدراسة 
 الأخرى مع نوعية الحياة والرضا عن العلاج.
مريًضا في هذه الدراسة من مستشفيين ومركز  05أشهر، وخلال هذه الفترة، تم تضمين  8تم اجراء هذه الدراسة على مدار فترة 
 تحت إشراف طبيبة أخصائية للروماتيزم. و قطاع غزة  , القدسمتخصص لطب الأطفال في الضفة الغربية
مريض وأولياء أمورهم. واحد من هذه الاستبيانات هو قياس جودة حياة الأطفال ،حيث تم استخدام  05تم اعطاء الاستبيانات إلى 
ن العلاج ، حيث تم استخدام . كان الاستبيان الآخر هو قياس رضا المرضى ع selacS eroC cireneG LQsdePنموذج 
 . 4.1) الإصدار MQSTاستبيان رضا المرضى عن العلاج (
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استبيان قياس رضا المرضى عن العلاج، بالإضافة و  قياس جودة حياة الأطفال في هذه الدراسة، لاحظنا درجات كلا من استبيان 
إلى مقارنتها بالعوامل الأخرى بما في ذلك مكان إقامة المعيشة، والعلاقة الأسرية مع المرضى، بالإضافة إلى مستوى تعليم 
وذلك للكشف عن تأثير  النقل،الوالدين، ونوع المنزل، وعدد أفراد الأسرة، والدخل الشهري للوالدين، حالة عمل الوالدين، وتكلفة 
 MQSTو   LQsdePعلى الوضع الاقتصادي. علاوة على ذلك ، تم فحص مدى الارتباط بين  التهاب المفاصل مجهول السبب
وعلاقتهم . كما تم استكشاف وزن المريض وارتفاعه ومؤشر كتلة الجسم  التهاب المفاصل مجهول السببمع كل نوع فرعي من 
 .LQsdePو MQST مع
ولم  المتوسط؛أشارت النتائج إلى أن جميع المرضى لجميع الأعمار لديهم نوعية الحياة وكذلك درجات رضا العلاج أعلى من 
 . بناءا على نتائج الاهل ى عن العلاجالمرض استبيان رضايكن هناك تأثير كبير إلا مع مجال الرضا العالمي في 
 في حالة الفرضية والمقارنات، أظهرت النتائج عدم وجود تأثير كبير باستثناء الحالات التالية: 
الى  بالإضافة .في حساب الفئات العمرية للأطفالالفعالية في استبيان رضا المرضى عن العلاج  حالة عمل الوالدين مع مجال 
راحة في استبيان رضا المرضى عن العلاج ، دون حساب الفئات العمرية الحالة عمل الوالدين مع مجال  واضح في تأثيروجود 
  للأطفال.
 حساب الفئات العمرية للأطفال.عدم  ةقياس جودة حياة الأطفال , في حال أفراد الأسرة مع مجال الوظيفة البدنية في استبيان عدد
قياس جودة حياة الأطفال و استبيان رضا المرضى عن العلاج  ارتباط الوزن والطول للأطفال مع استبيانفي حالة تحليل مدى 
قياس جودة حياة الأطفال ، ولكن كان  ، أظهرت النتائج أن كلا من الوزن والطول لم يكشفا عن أي تأثير كبير على استبيان
ضا المرضى عن العلاج ، وفي حالة وزن الأطفال كان هناك تأثير هناك تأثير كبير على مجال الرضا العالمي في  استبيان ر 
 .كبير مع مجال الآثار الجانبية في  استبيان رضا المرضى عن العلاج 
 واستبيان رضاقياس جودة حياة الأطفال  كان هناك تأثيرات كبيرة على كل من مجالات استبيان الجسم،بالنسبة لمؤشر كتلة 
ومجالات الأداء  قياس جودة حياة الأطفال كان هناك تأثير كبير في الأداء العاطفي ة استبيانفي حال العلاج،المرضى عن 
 .تأثير بين مؤشر كتلة الجسم ونطاق الراحة  ناكهكان  العلاج،رضا المرضى عن اما بالنسبة لاستبيان  .النفسي الاجتماعي
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مرضى يعانون من التهاب القزحية كأحد المضاعفات. بالنسبة  4وفًقا للمعلومات المستخرجة من سجلات المريض ، كان هناك 
للأدوية المستخدمة ، كان الأكثر استخداًما مع المرضى بريدنيزون ، ميثوتريكسات ، إيبوبروفين ، حمض الفوليك. البيولوجيا مثل 
 bamumiladA.، و  bamuzilicoT،  tpecatabA،  tpecrenatE،  bamixilfni
 ، ) 05 من أعلى الدرجات كانت( العلاج ورضا الحياة جودةالخمسين بأعلى من متوسط  AIJفي الختام ، يتمتع جميع مرضى 
 أفضل.  LoQRH إلى العليا الدرجات تشير حيث
، وكان  7-5عاًما ، وكان الأسوأ مع الفئة العمرية  81-31كان في الفئة العمرية  LQsdePتشير نتائجنا إلى أن أفضل 
عاًما. قد تتأثر هذه النتائج لأن عدد المرضى لم يكن بهذا  81-31أفضل مع المرضى الذين تتراوح أعمارهم بين  MQST
 في حياة الأطفال. التهاب المفاصل مجهول السببلذلك هناك حاجة إلى مزيد من التحقيق حول آثار  الحجم،
 
